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ABSTRACT OF THE THESIS 
EXHALED BREATH ANALYSIS OF SMOKERS USING CMV-GC/MS 
by 
D’Nisha Darquise Hamblin 
Florida International University, 2016 
Miami, Florida 
Professor José Almirall, Major Professor 
The aim of this research was to demonstrate the potential of the novel pre-
concentration device, capillary microextraction of volatiles (CMV), for breath 
analysis. The CMV offers dynamic sampling of volatile organic compounds with 
its simple coupling to a GC inlet for GC/MS analysis, avoiding expensive thermal 
desorption instrumentation needed for sorbent tubes, as well as an increased 
surface area over a single SPME fiber. CMV collectively identified 119 
compounds in the breath of 13 self-reported smokers and 7 nonsmokers. The 
presence and intensity of twelve compounds were used to classify all the 
nonsmokers 100% of the time using Principal Component Analysis to elucidate 
the groupings. In some cases, nicotine was not detected in smokers and they 
were confused with the nonsmokers. Nicotine was detected in the breath of 69% 
of smokers with an average mass of 143 ± 31 pg for cigarette smokers from the 
approximate 5 L sample of breath collected. The successful use of the CMV 
sampler and preconcentration of breath to distinguish between smokers and 
nonsmokers served as a proof of concept for future applications of the CMV for 
detection of marijuana smokers’ breath for impaired driver management. 
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CHAPTER 1: INTRODUCTION & RESEARCH MOTIVATION 
1.0 Introduction to Breath Analysis 
 
Exhaled breath analysis is a type of trace gas analysis where chemical 
compounds within a breath matrix are searched for information detailing the 
status of the body [1]. A breath matrix is composed of two fractions: gas phase 
volatile organic compounds (VOCs) and non-volatile compounds (NVOCs) 
carried in aerosol particles [2]. The aerosol fraction can consist of proteins, 
signaling molecules, dissolved inorganic compounds, bacteria, and viruses [2] 
which are expected to originate from the respiratory track lining fluid [3]. 
Collectively the gas and aerosol phase of the breath profile totals ~300-500 
identified chemical compounds [4]. These compounds could be of endogenous or 
exogenous origin. Endogenous compounds are age, gender, ethnicity and health 
dependent [5] and are the result of normal metabolic activity or pathological 
disorders [6]. Exogenous compounds originate from ingestion of food or 
medicine, inhalation of ambient air contaminants from chemical environments as 
well as exercise and smoking activities [7].  One of the earliest recognized 
applications of breath analysis was blood alcohol concentration determination [8]. 
However, unlike alcohol, numerous other breath pollutants are expected to have 
concentrations orders of magnitude smaller, in the range of µmol/L to fmol/L 
(ppm/v to ppt/v) [9]. Measurement of endogenous compounds in breath can 
serve as a diagnostic tool for cancer and respiratory infections [10]. In exhaled 
breath analysis for disease diagnostics it is important to measure changes in 
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concentration, as disease onset is linked to concentration changed instead of the 
presence and absence of unique biomarkers [7]. As the concentration of 
compounds in breath are expected to be low, it is important to have necessary 
sampling methodologies to capture them.  
2.0 Breath Sampling: Pre-concentration 
 
The lack of a standard sampling procedure for exhaled breath analysis 
capable of sensitive detection, has sparked an onset of sampling techniques 
proposing resolution to the sensitivity issue. One technique, pre-concentration, 
operates on the bases of absorption processes. Pre-concentration sampling 
techniques permit portable sample collection, which is important for breath 
diagnostic testing studies; as onsite collection warrants improved sample 
integrity. Pre-concentration has been achieved through sorbent and fiber 
technology where VOCs were trapped within sorbents or absorbed to coated 
fibers. Activated charcoal, graphitized carbon, carbon molecular sieves, metal 
oxides and porous organic polymers have also been used for pre-concentration 
[11]. Not all of these pre-concentration technologies can be advantageous in the 
use of breath sampling as temperature limitations or high artefact levels may 
interfere with trace analysis [12]. Molecular sieves, graphite carbon and tenax® 
have high break through volumes, in that they do not retain absorption of 
molecules. Some sorbents may be hydrophilic and therefore not suitable for the 
sampling of water saturated breath samples [13]. Tenax® technology is least 
affected by water [12,14]. Solid phase microextraction (SPME) fibers have often 
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been deemed the “gold standard” in breath analysis [15], however the surface 
area of its single fiber limits the quantity of substances that can be absorbed [13]. 
It would be of interest to investigate a new technology that embodies the 
characteristics of a SPME fiber, but with increased surface area. Representation 
of a solution to the previously described sampling shortcomings have been 
exhibited by a novel sorbent technology known as the capillary microextraction of 
volatiles (CMV) device.  
2.1 Pre-concentration Device: Capillary Microextraction of Volatiles 
 
The CMV device used in the execution of this research was a novel 
sorbent filled mini capillary tube that was thermally desorbed through the 
coupling to a gas chromatographic instrument’s inlet. The CMV was 
manufactured in the Almirall research lab and consists of an open ended 2 cm 
long glass capillary glass tube packed with precut 2 mm wide by 2 cm long strips 
of a polydimethylsiloxane (PDMS) coated glass fiber filter called a planar solid 
phase microextraction (PSPME) device. The detailed chemical configuration of 
this device has been described elsewhere [16].  
The PSPME device can be used as a pre-concentration filter for sample 
introduction into an Ion Mobility Spectrometer (IMS) for analysis. The PSPME 
has demonstrated its absorption capabilities of illicit drugs and explosives by 
dynamic sampling [17]. The restructure of the PSPME filter into the CMV design 
allowed for the exploration of other applications additional to explosives and 
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drugs. The CMV has been used to demonstrate absorption of volatiles in air [18], 
explosives [16], gunshot residue [19] and drugs [20].  
The use of the CMV as a sampling device is advantageous because the 
design allows for simple collection and easy transport and storage of the device 
until analysis. The capillary glass tube design allows for the ability of the device 
to be reusable without contamination concern. Studies of explosive volatile 
headspace collection indicated the CMV devices’ ability to retain at least 70% of 
analyte mass after storage at 23°C for more than 60 hours [16]. The PDMS 
sorbent coating of the CMV is reported to be ~0.05 m2 thick with a calculated 
phase volume of 50 mm3 [16]. An increased phase volume for absorption 
extraction allows for a quantitatively better extraction with the CMV than from any 
other device (i.e., SPME). The PDMS coating of the CMV encounters strong 
polar interactions through hydrogen bonding of the siloxane groups of the           
[-Si(CH3)2)O-] PDMS repeating unit as well as van der Waals interactions with 
samples containing alkyl groups [21]. The CMV device is thermally stable to at 
least 300°C [Patent US20140260974 A1] allowing for suitable desorption of high 
molecular weight compounds from the CMV coating.  
 
 
 
 
Figure 1: Illustrations of the novel CMV sorbent device. 
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3.0 Research Hypothesis & Goals 
The focus of this research was to evaluate and describe the CMV’s 
potential as a sampling device for exhaled breath analysis of gas phase volatiles 
and aerosol particulates by thermal desorption gas chromatography mass 
spectrometry (GC/MS). Evaluation focused on two aims: 
1. The CMV’s ability to identify individual compounds in breath samples 
of both exogenous and endogenous origin to establish a breath 
profile. 
2. The CMV’s ability to use the breath profiles to distinguish between two 
groups (smokers and nonsmokers) which are expected to have 
different profiles based on the presence or absence of significant 
biomarkers. Selected biomarker of this research is nicotine. 
It was hypothesized that the CMV would capable of absorbing multiple 
analytes in order to obtain a breath profile, as well as to quantifiably detect low 
levels of significant biomarkers capable of distinguishing between smoker and 
nonsmoker exhale breath profiles.  
4.0 Significance of Research 
The CMV used as a sampling device would be able to perform indirect 
sampling and pre-concentration of a breath matrix. Success of this proof of 
concept idea using CMV as a part of a breath sampling device would be 
beneficial to breath analysis in clinical and forensic applications. The sensitivity of 
the device could be clinically relevant to cancer & medical condition diagnostics. 
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Forensically, the techniques’ ability to detect narcotics would aid in the 
management and enforcement of drug impaired drivers in traffic patrols, or 
workplace drug testing; similarly, to the commercialization and utilization of 
breathalyzers for drunk drivers. The CMV’s forensic application of drug detection 
can prove beneficial to address the concerns for managing wide spread 
marijuana legalization.  
5.0 Overview of Research Study  
The current study proposed an alternative sampling technique that would 
be applicable for the detection and tentative identification of both gas and aerosol 
phase exhaled breath. Nicotine, the addictive substance of tobacco products was 
chosen as the target analyte to access the sensitivity and capacity of the CMV to 
sample and pre-concentrate a range of low concentrations. Its selection as a 
significant biomarker was linked to its anticipated ability to distinguish between 
smoker and nonsmokers in this study. This thesis has thus introduced the 
concept of breath analysis (Chapter 1), and will later explain the fundamentals of 
the instrumentation used to execute the research (Chapter 2), describe the 
method development of operational parameters and breath sampling protocol 
(Chapter 3), discuss some applications of breath analysis (Chapter 4), analyze 
and statistically evaluate breath samples of volunteers of this research study 
(Chapter 5), review the limitations in the study’s protocol and suggestions for 
future work (Chapter 6), evaluate  an independent work investigating the 
headspace of marijuana plant material as it relates to future research in 
7 
	
marijuana breath detection (Chapter 7), and finally concluding with remarks and 
discussion of the CMV’s overall performance (Chapter 8).   
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CHAPTER 2: INSTRUMENTATION BACKGROUND  
The analytical process of analyzing volatiles and aerosols in exhaled 
breath involves sampling and sample preparation before introduction into 
instrumentation capable of separating and quantifying the complex mixture. 
1.0 Indirect and Direct Analysis of Breath  
Measurement techniques for breath are often categorized into two 
approaches: indirect and direct analysis. Direct analysis approaches, often 
referred to as online measuring techniques, are capable of real time analysis of 
breath samples. Indirect analysis approaches are referred to as offline measuring 
techniques, where breath samples are collected and trapped before being 
transferred to an analytical instrument for analysis [14, 22].  
1.1 Online Instrumentation  
Real time analysis of exhaled breath can be satisfactory for collective and 
continuous exhaled breath research studies. Real time devices such as proton 
transfer reaction time of flight mass spectrometry (PTR-TOF-MS) [23-25], 
selected ion flow tube mass spectrometry (SIFT-MS) [26], single photon 
ionization time of flight mass spectrometry (SPI-TOF-MS) [27] and microwave 
plasma torch time of flight mass spectrometry (MPT-TOF-MS) [28] are often used 
in breath analysis for monitoring breath volume and breathing rate. An example 
of a sensor based real time device used in exhaled breath analysis is called an 
electronic nose. These real time devices have been used in research studies 
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examining the exogenous compounds found in exhaled breath as a result of 
smoking activities. Two examples will be reviewed.  
1.1.1 Proton Transfer Reaction Time of Flight Mass Spectrometry  
	
Proton Transfer Reaction Time of Flight Mass Spectrometry is a one 
dimensional technique that operates under proton transfer reactions [23] and 
characterizes compounds by their mass [24]. After collection of the sample via a 
tedlar bag the mixed exhaled breath of 370 volunteers with a smoking history 
were analyzed by PTR-TOF-MS. In this study by Kushch and associates, seven 
significant VOCs of smokers were identified corresponding to m/z product ions 
28, 42, 69, 79, 93, 97 and 123. Acetonitrile was one of the major VOCs of the 
smoker breath profile identified [25]. Another PTR-TOF-MS study by Kohl and 
associates confirmed acetonitrile as a marker in the exhaled breath of seventy-
two women (26% smokers) over a 12-month period. The study revealed that 
acetonitrile and benzene unambiguously identify smokers from nonsmokers by 
their high fraction in the breath samples. Acetonitrile’s concentration in breath 
has such a high fraction that it is detectable over a few days [29]. 
1.1.2 Electronic Nose 
	
The electronic nose is a miniature portable device composed of a 
nanocomposite array of 32 organic polymer sensors [30]. It operates as a lab on 
a chip system and has also been applied to exhaled smoker breath analysis. In a 
research study by Cheng and associates, the breath of 15 smokers (46%) and 
nonsmokers (56%) were analyzed by the Cyranose 320 twelve hours after their 
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last cigarette was smoked. A significant difference between the two groups’ 
breath profiles was determined with a high degree of accuracy, as determined by 
an algorithm that can differentiate mixtures [31]. 
1.1.3 Pros & Cons 
Although these real time devices are capable of analyzing the constituents 
of a smokers’ exhaled breath profile with high sensitivity and have the ability to 
distinguish between smokers and nonsmokers, the techniques have their 
drawbacks. The PTR-TOF-MS technique can be used as a standardized 
collection method for large screenings because it can use a single breath for 
repeated measurements in its short and highly reproducible analyses [23]. 
However, PTR-TOF-MS is not suitable for diagnostic identification of unknowns 
without prior calibration [24]. Online ionization methods such as PTR-TOF-MS 
have difficulties separating isobaric compounds, have contamination between 
successive measurements as a consequence of o-ring placement [25], and have 
difficulties measuring compounds with low proton affinity such as alkanes [23]. 
The main drawback of the electronic nose is its susceptibility to baseline drift and 
its lack of contribution to the identity of the compounds involved in its 
classification of smoker and nonsmokers [30]. A real time breath analysis 
techniques’ ability to eliminate a sample pre-concentration step may not be as 
favorable as techniques that use sample pre-concentration. 
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1.2 Offline Instrumentation  
The indirect analysis of exhaled breath often involves the collection and 
trapping of a breath sample onto a sorbent to pre-concentrate it followed by one 
of two sample extraction methods: solvent desorption (SD) or thermal desorption 
(TD). The use of these collection, trapping and extraction techniques will be 
reviewed in offline instrumentation techniques.  
1.2.1 Collection  
Examples of breath collection devices used to contain the exhaled breath 
sample before pre-concentration are the Bio-VOC sampler [9, 32, 33], and tedlar 
bags [34-36]. Depending on the size of the collection device, it may be designed 
to collect a sample of a single exhalation. The commercially available Bio-VOC 
sampler was designed for alveolar breath collection of a 100 ml sample [32]. The 
commercially available tedlar bags are available in varying volumes as well as in 
transparent and black films that provide UV-protection [37].       
Collection of a sample into a collecting device followed by subsequent 
transfer to a pre-concentration device has potential faults. Indirect analysis 
processes are susceptible to sample volume restrictions, sample loss and 
sample contamination. The limitation of volume restrictions is observed with the 
use of the Bio-VOC sampler. Studies by Kwak and associates demonstrated that 
the sampler’s actual volume capacity is 80% of what is reported [32]. Volume 
constrictions result in the action of continuous uses which are limited to 5 
transfers for the Bio-VOC sampler [32]. Multiple transfers of the sample between 
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containers increases the chances of sample loss and compromises 
reproducibility during transfer [2]. In some research studies, the breath sample is 
transferred from tedlar bags via syringe into glass headspace vials before 
exposure to SPME fibers [2, 36, 38]. Sample loss may also occur as 
consequence of the adsorption and diffusion characteristics of the collection 
devices’ surface material [22, 37]. Teflon has been identified as the material that 
can avoid adsorption of VOCs to the walls of the collection container [23]. 
Additionally, a collection containers’ material may emit VOCs that can 
contaminate the exhaled breath sample. The plastic valves of the tedlar bags 
may emit VOCs of alkanes and plasticizers, subsequently causing lengthy 
cleaning processes of up to 2 hours with an inert gas before use [23, 39].  
Suggested solutions to these potential faults are to bypass the collection 
step and directly pre-concentrate samples. A flow through sampling device would 
integrate sampling collection and pre-concentration into one step. Proposal of 
such a flow through system using the CMV will be discussed in a future chapter 
(Chapter 3, Section 4.1).  
1.2.2 Trapping  
Examples of sorbent materials used for pre-concentration of exhaled 
breath samples are activated carbon sorbents [8], SPME fibers [36, 38, 40, 41] 
and Tenax® sorbent tubes [33, 42] followed by analytical techniques such as 
GC/MS [8, 9, 35, 40, 41] or ion mobility spectrometry [42] analysis. During the 
early stages of exhaled breath analysis, researchers often collected breath into a 
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reservoir and then pumped the sample through an activated carbon sorbent for 
solvent desorption extraction [8]. As the scientific community began to transition 
away from SD extraction, alternative sorbent types had to be considered as the 
strength, hydrophilicity, and reactivity of charcoal based sorbents were 
incompatible with the newly established TD extraction technique [12]. The 
alternative sorbents of Tenax® sorbents and SPME fibers will be reviewed. 
1.2.2.1 Solid Phase Microextraction Fibers 
Solid phase microextraction fiber technology was first commercially 
introduced in 1998 by Supelco and is now the most widely used sampling 
method [5]. A SPME fiber follows non-exhaustive extraction fundamentals [5] and 
pre-concentrates breath constituents as the sample is statically extracted in a 
closed headspace system [22]. The microextraction process described by mass 
conservation is considered complete when analyte concentration reaches 
equilibrium in the sample matrix and the fiber coating [5]. The porous polymer 
fiber coating of the SPME is usually nonpolar PDMS because of its low cost and 
strong adhesion to the substrate [5]. The SPME fiber has small surface area of 
9.4 x 10-6 m2 and a phase volume of 0.612 mm3 [17]. The SPME technology 
offers rapid sampling, high resolution, and low detection limits for breath 
samples. Samples can be stored on the fiber for 8 hours without any significant 
loss of analytes [15].		
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1.2.2.2 Tenax® sorbent tubes  
Tenax® sorbent tubes contain porous polymer particles of a 60-80 mesh 
size [12] or other sorbents like chromosorb, porapak, or spherocarb [43]. A 
Tenax® sorbent tube pre-concentrates breath constituents as the sample is 
pumped from the collection device onto the tubes’ column [22] following 
exhaustive extraction fundamentals [5]. Exhaustive techniques completely 
remove analytes from the matrix into the extraction phase. The porous polymer 
extraction phase dispersed on the supporting mesh material is usually Poly(2,6-
diphenylphenylene oxide) (PPPO) [44]. When properly conditioned Tenax® 
sorbents have minimum background artefacts at 0.1-1.0 ng levels preventing the 
masking of detectable nanogram level breath markers [12]. The most favorable 
advantage of the use of Tenax® in breath analysis is its ability to repel water as 
breath samples can be vapor rich [14]. The sorbent provides suitable absorption 
and desorption for aliphatic hydrocarbons C7 to C10 and aromatics as well as for 
other high boilers [43]. The advertised surface area of an 80/100 mesh Tenax® 
tube is 35 m2/g of mesh [44]. 
1.2.3 Extraction 
Solvent desorption is carbon absorption followed by extraction via a 
versatile desorbing liquid [45]. Solvent desorption is compatible with high 
molecular mass and thermally unstable compounds and allows the pre-
concentration of high volumes of air [11]. The adoption of increased sample 
volume is a consequence of the decreased method sensitivity caused by sample 
dilution [11, 45, 46]. Evaporative loss of the sample is observed during the 
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solvent reduction stage [46] and it is reported that only 1-5% of the sample is 
actually introduced into the GC system [47]. Solvent use is generally criticized 
because of toxic waste production, but additionally the solvent used in SD can 
cause analytical interference [46].    
Thermal desorption extraction is a two stage extraction process using heat 
and a flow of inert gas [46]. Thermal desorption has been shown to be a more 
appropriate extraction technique than SD in studies by Ramirez and associates. 
In their study, of 90 industrial and urban environment VOCs, 18 out of 90 of the 
VOCs were found using SD extraction by carbon disulfide solvent desorption of 
charcoal tubes, while 50 out of 90 of the VOCs were found using TD extraction of 
Tenax® sorbent tubes [11]. The repeatability, recovery, detection, and 
quantification merit characteristics of TD were generally better than SD.  A 
different air study of environmental pollutants was in agreement that tenax® TD 
has statistically better repeatability, recovery and temporal resolution than SD by 
an acetone and methyl tertiary butyl ether (MTBE) desorbing liquid [46].  
Although SD has attractive properties, the advantages of the TD extraction 
technique are more suitable criteria for the analysis of exhaled breath because of 
its superior selectivity and sensitivity [5, 12]. Its pre-concentration does not 
require large volumes as SD extraction techniques would, preventing fatigue of 
subjects caused by the collection of large volumes of breath over an extended 
period [22, 23]. The advantages of TD extraction with Tenax® sorbents can be 
alternatively applied to the proposed CMV sorbent device.   
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2.0 Indirect Analysis of Breath using CMV-GC/MS  
After evaluation of the available analytical approaches to breath analysis, 
GC/MS was selected as the appropriate technique relevant for the purposes of 
this thesis research, because of its adaptability to the TD of the CMV device and 
analysis of volatile, thermally stable species. Gas chromatography mass 
spectrometry is highly discriminative in its separation preventing overlap 
observed in online instrumentation and is capable of the identification of 
unknowns by mass spectrum comparisons to online computer libraries. Although 
GC/MS offers low detection limits and rapid sampling, the identification aspect of 
its analysis can be tedious and time consuming for complex matrices like breath 
[48]. The principles of instrumental operation of a GC/MS system for the analysis 
of exhaled breath using CMV will be described. A schematic of a basic GC 
system can be seen in Figure 2. 
 
Source: http://www.chromacademy.com/resolvernovember2010_understanding_gcms_part_1.html 
Figure 2: Schematic of a GC/MS instrument. 
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2.1 Sample Introduction 
Sample introduction into the gas chromatographic systems’ inlet can be of 
liquid or gas phase. Liquid standard samples for calibration determination were 
introduced by an Agilent G4513A automatic liquid sampler (Santa Clara, CA) 
incorporated with a 10 µL Agilent gold standard syringe (Santa Clara, CA).  Gas 
phase exhaled breath samples pre-concentrated on CMV devices were 
introduced into the inlet of the GC system via the coupled Agilent thermal 
separation probe (TSP) adapter (Santa Clara, CA) which facilitated sample 
transfer as seen in Figure 3. This apparatus was directly connected to the inlet 
compared to tubular/column connections of the bulky and expensive thermal 
desorption unit used for Tenax® sorbent tube analysis. During introduction, the 
molecular bonds of the analytes absorbed on the CMV were broken by heat 
applied in the inlet assisting the desorption process.  
Figure 3: Thermal separation probe coupled to GC inlet. 
A GC inlet operates under either a split or splitless injection mode. In split 
injection mode, the sample was contained within a splitless Restek ultra inert sky 
liner (Bellefonte, PA) and a percentage was carried to the column and the 
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remaining percentage was carried between the liner and the inlet body to the spilt 
line where the sample and helium carrier gas was released. The percent arriving 
at the columns’ entrance was dependent on the split ratio and gas flow rate. In 
splitless injection mode the entire sample reached the column. The split 
operational modes affect peak shape of the resulting chromatogram during 
separation. 
2.2 Gas Chromatography  
After sample introduction, separation of the gaseous sample in an Agilent 
7890A GC system (Santa Clara, CA) occurred on a HP-5ms capillary column 
(29.17 m x 0.25 mm x 0.25 µm) as the gaseous sample molecules were carried 
by the helium carrier gas. The temperature gradient applied to the column in a 
heated oven affected separation and elution of sample molecules depending on 
their volatility. The time-based separation is graphically illustrated by a 
chromatogram. The gas chromatographic technique only performs the separation 
of the complex breath samples, and needs to be coupled to a detection 
technique for identification of breath components. 
2.3 Mass Spectrometry 
Analysis of the separated sample from the GC system occurred in a 
vacuum sealed Agilent 5975C Inert XL MSD mass spectrometer with triple axis 
detector (Santa Clara, CA). The MS can be composed of many combinations of 
ion sources, mass analyzers and detectors depending on their combined 
selectivity, sensitivity, and identification abilities. The MS in the present research 
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utilized electron impact ionization (EI) at 230°C, where neutral sample molecules 
were bombarded with 70eV electrons causing breakdown of the molecule into 
positive ions. The positive ions were filtered and separated by their mass 
according to an electromagnetic field produced in a single quadrupole mass 
analyzer. Electron impact ionization and the quadrupole are the most frequently 
used source and mass analyzer. The mass selective detector measured the 
filtered ions’ characteristic mass-to-charge ratio and plots their distribution 
according to fragment intensities in a mass spectrum. Information was acquired 
in both scan mode and select ion monitoring (SIM) mode. The unity mass 
resolution of the MS has parts per billion (ppb) detection capability suitable for 
detection of trace exhaled breath volatile and aerosol concentrations.
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CHAPTER 3: METHOD DEVELOPMENT  
1.0 Parameter Programming  
A detailed literature review of gas chromatographic temperature programs 
used in drug breath detection analysis was completed as a starting basis in the 
method development for this research. Studies reported lengthy comprehensive 
methods greater than 30 minutes [33, 36, 40, 41, 50], focusing separation of the 
lower molecular weight volatiles. For the purpose of the current research, the 
temperature program will reflect a shorter screening method specifically adjusted 
for detection and resolution of the target compounds.    
The oven temperature was programmed for 2 min at 40˚C, then 25˚C/min 
to 260˚C, and finally at 260˚C for 10 min. The full chromatographic run totaled 
20.8 minutes. The injector was operated in splitless mode at an initial 
temperature of 250˚C until optimization occurred. The transfer line was 
maintained at 280˚C. The constant GC column flow of helium was 1.2 ml/min. 
The mass spectrometer simultaneously collected total ion chromatogram (TIC) 
and SIM data over the acquisition range 40-340 m/z. The selected ion monitoring 
for nicotine were 84, 133, and 162 m/z. The selected ion monitoring for Δ9-
tetrahydrocannabinol (THC) ions were 299, 271, 231, 314 m/z and were set to 
start at the 14-minute mark during the method.  Since the SIM groups contain 
between 2-5 ions a dwell time of 50 msec was chosen allowing for 4.5 cycles/sec 
resulting in 17 SIM cycles per peak. Separate methods were essential for 
analysis of liquid standard solutions and CMV breath samples, as standard 
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solutions require a solvent delay of 4 minutes because solutions contain 
methanol (MeOH) solvent.  
1.1 Optimization of Parameters 
As a result of the differences in physical characteristics of the target 
analytes, the GC inlet temperatures were optimized for simultaneous detection to 
maximize instrument response. The literature review revealed that the GC inlet 
temperature ranged between 250˚C to 300˚C for nicotine and THC in air studies 
[51, 52]. The GC inlet temperature study examined temperatures 250˚C -300˚C 
in 10 degree increments for the method previously described (Chapter 3, Section 
1.0).  A 15 ppm nicotine and THC methanol solution mixture was used to spike 1 
µL of solution onto a CMV before introduction into the GC system via a thermal 
desorption probe. Duplicate spikes of the solution were made for each of the six 
GC inlet temperatures. Data were analyzed for the peak area under the curve 
(AUC) and duplicate areas were averaged. Results of the peak area response 
comparison for individual inlet temperatures can be seen in Figure 4.  Although 
250˚C seems to be the optimum GC inlet temperature for nicotine alone, the 
temperature of 270˚C is the optimum temperature for simultaneous detection of 
both target analytes as they show a maximum response of peak area in their SIM 
data. All methods reflected this justified GC inlet temperature in successive 
experiments. 
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Figure 4: Peak area response of SIM data for target analytes NIC (grey) and 
THC (white) over inlet temperature ranges 250˚C - 300˚C. 
1.2 Retention Time Locking  
After optimization of the GC inlet temperature, the experimental method 
was locked for the retention times of the analytes of interest. The retention time 
locking (RTL) procedure in method development accounts for variation in peak 
shifts as the result of maintenance and chromatographic degradation. The 
procedure allows for a close match of retention times by making an adjustment to 
the inlet pressure at four predefined pressures ±10% and ±20% of the target 
pressure of the original method [53]. An automatic sampler was used to make the 
five direct injections of 1 µL of a 15 ppm nicotine MeOH solution into the GC/MS 
at the four predefined pressures and the target pressure. The software selects 
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and integrates the five nicotine peaks and plots their retention times with respect 
to the associated pressures in a calibration curve. The curve can then be used to 
correct the locked method to ensure proper confirmation and identification of the 
target analyte under circumstances of instrument drift. The retention times were 
9.404, 8.906, 8.724, 8.485, and 8.282 minutes respective to pressures of 
negative percentage to positive percentage difference.   
2.0 Analyte Calibration and Retention Time Determination 
The target analytes were examined by their retention time for the correct 
identification of the compound in a biological sample. The target analytes for the 
proposed experiments were nicotine (NIC) and ∆9-tetrahydrocanabinnol (THC).  
 
Figure 5: Chemical structure of Nicotine (left) & THC (right). 
2.0.1 NIC  
Experiments of 10 ppm nicotine MeOH solutions were used to examine 
the retention time of both a liquid and CMV method. The retention time of the 
direct liquid injection of the standard nicotine was 8.745 min over a range of 8.72-
8.90 minutes for SIM mode. The retention time of the nicotine liquid standard 
spiked onto the CMV was 8.732 min over a range of 8.70-8.80 minutes for SIM 
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mode. Analyzing the data of the mass spectrum of a 10 ppm nicotine solution 
spiked onto a CMV seen in Figure 6 reveals a molecular ion, M+, of 162 with 
characteristic fragments of m/z 84 and 133.  
 
	
Figure 6: Chromatogram of SIM data (top) and mass spectrum (bottom) of a 10 
ppm, 1 µL liquid nicotine solution spiked onto CMV.  
The response of nicotine in the GC/MS was examined by calibration for 
both direct liquid injection and CMV spike introduction. The concentrations of 
-5.0E+05
1.5E+06
3.5E+06
5.5E+06
7.5E+06
9.5E+06
1.2E+07
1.4E+07
1.6E+07
8.7 8.72 8.74 8.76 8.78 8.8
Ab
un
da
nc
e 
Time (min)
0.0E+00
1.0E+06
2.0E+06
3.0E+06
4.0E+06
5.0E+06
6.0E+06
7.0E+06
8.0E+06
9.0E+06
41 50 56 63 69 76 82 88 94 10
0
10
6
11
2
11
8
12
4
12
9
13
5
14
2
14
8
15
5
16
1
16
8
17
5
Ab
un
da
nc
e
m/z
84
133
162
119926551
42
105
25 
	
nicotine examined in these experiments reflected a range that would be 
representative of low levels that would be expected in exhaled breath samples 
[24, 33, 54]. Seven nicotine MeOH mixture calibration points were examined: 10, 
50, 100, 200, 300, 400, 500 ppb. The seven calibration solutions were loaded 
into an auto sampler for a 1 µL direct liquid injection of each sample into the 
GC/MS for liquid calibration determination. For CMV calibration, the same 
solutions were used to spike 1 µL onto a CMV before manual introduction into 
the GC system via a thermal desorption probe. The CMV’s spiked end was noted 
for correct orientation during introduction into the GC/MS system. For each 
calibration instance, triplicate chromatographic runs of the solutions were made 
for each of the seven calibration points. Data acquisition was done by collecting 
both SIM and fullscan data, however data analysis occurred for SIM data only. 
The three response replicates of the SIM peak AUC were averaged and plotted 
against concentration for a linearity examination. Upon examination of the 
nicotine curve, points 10 and 50 ppb were removed as they deviated from the 
linearity of the curve. The remaining five points of the nicotine curve gave a linear 
response for both liquid (R2 = 0.9879) and CMV (R2 = 0.9806) employed 
methods as shown in Figure 7. The relative standard deviations (RSDs) for the 
majority of all liquid calibration nicotine mixture concentrations were less than 
5%, except for the 400 ppb solution which had 19% error. The RSDs for all CMV 
calibration nicotine mixture concentrations were less than 9%. The equations of 
the line and R-squared values for nicotine liquid and CMV calibration data are 
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presented in Table 1. Equations can be used for concentration determination of 
unknown nicotine presence in breath samples. 
 
Figure 7: Calibration curves of 1 µL liquid nicotine standard MeOH solutions 
injected (square) and 1 µL liquid nicotine standard MeOH solution spiked onto 
CMV (circle). 
2.0.2 THC 
Experiments of 10 ppm THC MeOH solutions were used to examine the 
retention time of both a liquid and CMV method. The retention time of the direct 
liquid injection of the THC standard was 15.874 min over a range of 15.80-15.90 
minutes for SIM mode. The retention time of the THC liquid standard spiked onto 
the CMV was 15.876 min over a range of 15.82-15.96 minutes for SIM mode. 
Analyzing the data of the mass spectrum of a 10 ppm THC solution spiked onto a 
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CMV seen in Figure 8 reveals a molecular ion, M+, of 314 with characteristic 
fragments of m/z 231, 271, and 299.   
 
 
 
 
 
 
 
 
Figure 8: Chromatogram of SIM data (top) and mass spectrum (bottom) of a 10 
ppm, 1 µL liquid THC solution spiked onto CMV.  
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expected in exhaled breath samples [55-58]. The six points gave a linear 
response for both liquid (R2 =0.9865) and CMV (R2 = 0.9798) employed methods 
as shown in Figure 9. The RSDs for all CMV calibration THC mixture 
concentrations were less than 10%. The RSDs for the majority of all liquid 
calibration THC mixture concentrations were less than 9%, except for the 400 
ppb solution which had 20.4% error. The equations of the line and R-squared 
values for THC liquid and CMV calibration data are presented in Table 1. 
Equations can be used for concentration determination of unknown THC 
presence in breath samples or marijuana plant headspace samples. 
Figure 9: Calibration curves of 1 µL liquid THC standard MeOH solutions 
(square) and 1 µL liquid THC standard MeOH solution spiked onto CMV (circle). 
R² = 0.9798
R² = 0.9865
0.0E+00
1.0E+04
2.0E+04
3.0E+04
4.0E+04
5.0E+04
6.0E+04
7.0E+04
8.0E+04
9.0E+04
1.0E+05
0 100 200 300 400 500
SI
M
 A
U
C
 (n
=3
)
Concentration (ppb)
THC CMV Spike THC Liquid Injection
29 
	
2.1 Detection Limit Determination 
The analytical method detection limit (MDL) and method quantification 
limit (MQL) of the analytes of interest response on the GC/MS were determined 
from the linear regression analysis. In the current research, MDL is defined as 
the lowest amount of target analyte that can be detected above background and 
the MQL as the statistically valid lowest amount of target analyte that can be 
detected in a standard free matrix. The MDL and MQL are determined from 
equations 1 and 2 respectively, where yB is blank signal and Sy/x is the standard 
deviation in the y-direction of the calculated regression line.   
                                           !"# = %& + 3)* +                    (1)  
                                          !,# = %& + 10)* +                                      (2) 
3.0 Conclusion 
A short suitable method was developed for simultaneous detection of the 
analytes of interest. A standard calibration was performed for proper identification 
of unknown samples by comparison of retention time and mass spectra as 
summarized in Table 1. Further experimentation reflected the methodologies 
developed in this chapter.  
Table 1: Summary of calibration data and figures of merit. 
  Equation of the Line R2 value MDL MQL 
Nicotine 
Liquid 
Injection y = 3822x - 342754 0.9879 61 pg 202 pg 
CMV spike y = 6326x - 488760 0.9806 77 pg 257 pg 
THC 
Liquid 
Injection y = 120x - 5759 0.9865 68 pg 228 pg 
CMV spike y = 153x + 12001 0.9798 84 pg 280 pg 
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4.0 Breath Sampling Analysis 
Reliable analysis of exhaled breath samples is dependent upon their 
sampling materials and sampling protocol. Sampling must be thoroughly 
controlled.  
4.1 Materials & Sampling Device Description 
Two sampling methodologies were proposed for use in the current 
research. The first method directly collected the exhaled breath into a transparent 
1 L Tedlar® bag purchased from Zefron International (Ocala, FL) by way of 
tubing connected to a disposable AlcoQuant mouthpiece purchased from West 
prime Healthcare (Chino, CA). The sample was dynamically drawn from the bag 
into the CMV using a Supelco MSA Elf escort sampling pump (Bellefonte, PA) at 
a set flow rate. The second method utilized a homemade flow through breath 
collection device (BCD) composed of the same AlcoQuant mouthpiece 
connected to a modified disposable polyethylene transfer pipette purchased from 
Fischer Scientific (Hudson, NH) directly coupled to the CMV. The AlcoQuant 
mouthpiece is equipped with a saliva trap to prevent contamination to the 
sample. Illustrations of the assembled devices are found in Figure 10.  
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Figure 10: (Top) Bag sampling method (Bottom) BCD sampling method. Mouth 
piece (1), plastic tubing (2), tedlar bag (3a), and CMV (3b).   
4.2 Sampling Protocol 
Sampling protocol development explored the differences between 
collection device type and breath portion sampled on a small sample population 
of three subjects. Ethical approval for human studies was obtained from the 
Institutional Review Board (IRB) (No 2015/0157) at Florida International 
University (FIU).  Upon completion of a single exhalation, the average adult with 
normal and healthy lung function exhales ~500 ml of air [9] which is composed of 
two portions: dead space and alveolar air. Dead space air exists in the upper 
airways and nasopharynx consisting of 150 ml of the totaled exhaled breath, 
while alveolar air from within the lung constitutes the remaining 350 ml portion of 
the breath [9]. Breath analysis can be performed with mixed breath consisting of 
3b	
2	 1	
3a	
2	 1	
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both exhaled breath portions or solely the alveolar portion depending on the 
expected sources of compounds detected. Since alveolar breath is generally 
used in research because of its sample reproducibility [22] alveolar samples were 
collected from the subjects directly into a CMV or into a tedlar bag followed by 
extraction via pump into a CMV. 
During recruitment, subjects were allowed to make an appointment for 
sample collection in the laboratory. One female reported an age within the 26-35 
age range and two males reported in the 18-25 age range were recruited. Details 
of the study were described to the individuals, stressing the importance of breath 
sampling occurrence within one hour of a completed smoking session. Any 
questions regarding research processes were answered and written consent was 
obtained after participation agreement. Subjects were given a copy of the 
consent form to keep for their records. Brief voluntary questionnaires were 
provided emphasizing their anonymity as they were de-identified by a unique 
code that linked the sample identification code to the collected breath sample but 
not the consent form. The unique code consisted of a number randomly 
generated which was coupled to an extension number distinguishing the 
nonsmoker controls (XX-00) from the smokers (XX-01). Questionnaire answers 
were used to determine if any documented factor accounted for any variation 
observed between samples. Sampling session time took approximately 15 
minutes. 
Before providing samples, subjects were briefly instructed on how the 
sampling devices worked. Breath sampling consisted of alveolar breath collection 
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into a 1 L tedlar bag followed by a consistent number of breaths through the 
homemade flow through sampling device directly connected to the CMV (Figure 
10). Each subject was provided with a new device for each sample collection. 
The total volume of breath collected from each collection device was 
approximately one liter varying in 4-5 alveolar breaths from subjects. The volatile 
chemical components of the breath remained adsorbed to the CMV after 
sampling until analysis. The CMVs were wrapped in aluminum foil and sealed in 
labeled glass vials and tedlar bags were also labeled accordingly as illustrated in 
Figure 11.  Packaged tubes and filled tedlar bags were stored on the bench top 
at room temperature only for a few hours (2-3 hours), since analysis could not be 
performed directly following sampling.  
 
Figure 11: Storage of collected exhaled breath samples by both methods. 
	
Before analysis by GC/MS, breath samples collected in the tedlar bags 
were extracted into a CMV by a vacuum pump as illustrated in Figure 12. The 
CMV tube was directly inserted into the GC using a thermal desorption probe. 
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The heat of the injection port desorbed the absorbed compounds off the CMV 
and the components were separated by gas chromatography and detected in the 
mass spectrometer. The peak associated with nicotine was quantitatively 
analyzed as well as concentration differences between the breath collection 
devices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Collection of the exhaled breath Tedlar® bag sample with a CMV 
connected pump. 
 
 
Table 2: Summary of the smokers’ self-reported questionnaire responses on their 
smoking habits and summarized sampling protocol for each subject.  
Subject 
ID 
Smoke 
Frequency 
Smoke 
Product 
Time 
since 
Smoked 
Number 
of 
breaths 
Bag 
extraction 
Flow 
Bag 
extraction 
Time 
02-01 3 times/wk Other 30 min 4 0.2 L/min 3 min 
01-01 Daily 
Marijuana 
Spliff + 
tobacco 
15 min 5 0.8 L/min 1 min 15 sec 
35-01 Twice Daily 
American 
Spirit 
(Mellow) 
15 min 5 0.8 L/min 1 min 15 sec 
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4.3 Results & Discussion 
Although subjects 01-01 and 35-01 self-reported smoking a tobacco 
product within the expected 1-hour detection window, nicotine was not detected 
in either sample. Subject 02-01 self-reported smoking a non-tobacco product so 
nicotine was not expected to be detectable. Although the non-tobacco product 
consumed by subject 02-01 was not identified in the questionnaire, his breath 
profile was examined for THC which was not detected in the breath sample. The 
remaining compounds shown in the breath profile chromatograms were 
examined and tentatively identified using the NIST 2008 and WILEY 2008 
libraries. An example overlay of a tedlar bag and BCD alveolar breath sample 
from subjects 35-01 and 01-01 are shown in Figures 13 and 14, respectively. The 
tentative compound identification of the breath samples is listed in Table 3. The 
breath profiles contained 30, 31, and 22 compounds collectively between both 
bag and BCD sampling for subjects 02-01, 35-01, and 01-01 respectively. The 
relative response of compounds in the tedlar bags were higher than those 
obtained with the BCD.  
Two compounds of intense response were observed only in the tedlar bag 
samples. The compounds were N, N – dimethyl acetamide and phenol which 
have both been identified as tedlar bag contaminants [25]. N,N-
dimethylacetamide is the solvent used to manufacture the tedlar film used in 
production of the bags, so it is expected that they will emit this compound [39]. 
Studies have shown that purging a bag decreases the contaminants  
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Figure 13: The overlay chromatogram of the exhaled breath profile from subject 35-01 from the bag sampling method 
(red) and the BCD sampling method (Blue). 
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Figure 14: The overlay chromatogram of the exhaled breath profile from subject 01-01 from the bag sampling method 
(red) and the BCD sampling method (Blue). 
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by 2 times [39]. However, purging can prove to be a lengthy process as some 
studies have reported cleaning times up to 2 hours before use [23]. The carry 
over potential of breath samples in breath analysis using tedlar bags were 
examined by nitrogen gas flushing after sample extraction into the CMV. Figure 
14 shows an overlay plot of the tedlar bag alveolar breath sample of subject 02-
01 (Black), and two nitrogen flush occurrences (Red & Blue, consecutively). The 
first nitrogen flush consisted of a single filling and emptying of the bag into a 
CMV. The second nitrogen flush occurrence consisted of five consecutive fillings 
and emptying of the bag into a CMV on the 5th empty cycle. There was a distinct 
decrease in response by a factor of 2.2 and 2.9 for the two respective 
contaminant compounds identified in the headspace of tedlar bags after multiple 
nitrogen flushes. There did not seem to be any significant carry over of the breath 
samples after cleaning with nitrogen. The bag sampling method may be suitable 
for reuse after proper cleaning.        
4.4 Conclusions 
 
To simplify the sampling protocol, the use of tedlar bags was excluded as 
their cost, reusability, and portability during sampling would prove problematic for 
current research. The presence of the two bag contaminants creates blind spots 
in the analysis because of their intensities [37]. Some studies suggest that 
contamination can be decreased 5-7 times by heating the bags to release the 
contaminants followed by subsequent gas purging [39]. However, these lengthy 
cleaning protocols [23] as well as the need for optimization before extraction  
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Table 3: Tentative identification of compounds in breath profiles of 
subjects in the sampling protocol study between the tedlar bag and the 
homemade CMV breath collection device. 
No. Compound 
Subject 
02-01 
Subject 
01-01 
Subject 
35-01 
Bag BCD Bag BCD Bag BCD 
1 2,4 – dimethyl- heptane     ü  
2 N,N-dimethyl Acetamide ü  ü  ü  
3 3-Phenylindole    ü   
4 α-pinene    ü   
5 phenol ü  ü  ü  
6 D-Limonene   ü ü ü ü 
7 7,9-dimethyl hexadecane     ü  
8 
1-methyl-4-(1-
methylehtyl)-1,4-
cyclohexadiene 
  ü 
 
ü   
9 3,6 – dimethyl decane     ü  
10 Benzyl Alcohol ü ü     
11 undecane ü ü ü    
12 nonanal ü ü  ü   
13 cyclododecane     ü  
14 Octanoic Acid ü ü     
15 2-(2-butoxyethoxy)-ethanol ü      
16 dodecane ü ü ü ü ü  
17 decanal ü ü  ü ü ü 
18 napthalene     ü ü 
19 2-phenoxy-ethanol ü ü     
20 nonanoic acid ü ü  ü   
21 2,7,10-trimethyl-dodecane   ü    
22 caprolactam ü ü  ü   
23 tridecane ü ü ü ü   
24 2,6,11-trimethyl-dodecane   ü  ü  
25 2,2,4,4,6,8,8 - heptamethyl nonane   ü    
26 3,7-dimethyl decane     ü  
27 tetradecane ü ü ü ü ü ü 
28 caryophyllene   ü ü   
29 Hexadecane   ü ü   
30 pristane     ü  
Table 3 (Continued on Next page) 
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Table 3 (Continued) 
31 3,7,11-trimethyl-1-dodecanol      ü 
32 9-Eicosyne      ü 
33 2,6,10,15-tetramethyl-
heptadecane   ü    
34 (Z)-6,10-dimethyl-5,9-undecadien-2-one ü ü     
35 pentadecane ü ü     
36 butylated hydroxytoluene   ü    
37 Dodecanoic Acid ü      
38 heptacosane   ü    
39 diethyl phthalate ü ü ü ü   
40 heptadecane ü ü ü ü   
41 Benzyl benzoate ü ü     
42 isopropyl myristate ü ü  ü   
43 Tetradecanoic Acid ü      
44 Pentadecanoic Acid ü      
45 nonadecane ü ü     
46 Cis-9-hexadecanoic acid ü      
47 n-hexadecanoic acid ü ü ü ü ü ü 
48 dibutyl phthalate    ü   
49 eicosane ü ü     
50 isopropyl palmitate ü ü ü ü ü ü 
51 heneicosane ü ü   ü ü 
52 squalene   ü    
53 Docosane       
54 octadecanoic acid   ü ü  ü 
55 Bisphenol A     ü ü 
56 tricosane ü    ü ü 
57 benzyl butyl phthalate    ü   
41 
	
  
Figure 15: The overlay chromatogram of the exhaled breath profile from subject 02-01 from the bag sampling method 
(black) and Nitrogen flush #1 (red) and nitrogen flush #2 (blue). Inset of overlay at 5.0-9.0 minutes. 
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would not be feasible for the short and impromptu sampling periods of this 
research. The exclusion of the tedlar bag also lifts the restriction of the volume of 
breath collected. The sole use of the BCD can allow for increased volume and 
number of breaths which may be more appropriate for the detection of the target 
analytes. Further simplification of the sampling protocol excluded the mouth 
washing stage before sampling, as well as changing the breath portion collected. 
Research examining exogenous compounds are likely to use mixed breath, since 
air in the airways mostly resemble environmental condition exposures [23]. The 
breath of smokers is likely to contain more exogenous compounds, so the 
collection of mixed breath (whole breath including dead space and alveolar air) 
was preferred over alveolar space breath alone. In summary, the new sampling 
protocol consisted of multiple mixed whole breaths through the BCD 
approximating to a volume of 5 liters or 10 breaths according to a study that 
proved that 23% of total mass exhaled particles are detectable after 10 
exhalations, suggesting a washout time [59, 60].
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CHAPTER 4: APPLICATIONS OF BREATH ANALYSIS 
Recent interests in breath analysis have popularized applications in fields 
other than the medical field.  
1.0 Breath Analysis of Narcotics 
The analysis of breath has become an attractive technique for the 
medicinal screening of diseases such as lung cancer [36, 41] and has recently 
been considered as a potential tool in drug detection [61] considering its 
noninvasive approach to sample collection. Additional attractive advantages of 
breath analysis are its ease, ability to be performed anywhere, and low cost per 
sample. The conventional methods for drug testing involve sampling blood, urine, 
saliva, sweat and hair. Matrix selection for drug testing is dependent upon the 
desired result as differentiating detection windows are observed. Some matrices, 
like hair, can reveal a history of drug use, while others like breath reveal recent 
drug use. Studies have reported similarities in volatile compounds identified in 
urine and plasma to those in breath [35], however some drugs may be more 
readily measured in breath than in blood [7]. 
Various volatile signatures of drugs of abuse and their metabolites have 
been detectable in breath. Beck and associates examined amphetamine, 
methamphetamine, 3,4-methylenedioxy-methamphetamine, codeine, 6-
acetylmorphine, cocaine, benzyolecgonine, methadone, buprenorphine, 
diazepam, oxazepam and THC [61]. Another study also examined cocaine and 
morphine, but additionally looked at fentanyl, sulfentanyl, naloxone, norfentanyl, 
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nicotine, and ү-butyrolactone [62]. Although multiple examples of drugs of abuse 
have been demonstrated as detectable in breath, the two drugs that will be 
further reviewed in detail are THC and nicotine. 
1.1 THC Breath Detection  
The first studies of marijuana detection in breath were conducted in the 
1970’s and have since then not been considered as a highly desirable 
noninvasive method of detection for marijuana usage [55, 58, 63]. Developments 
in the field of marijuana drug of abuse testing focused on drug detection in blood, 
urine and most recently oral fluid [64-66]. It was not until around 2010 that 
researchers at the Karolinska Insitutet began to further explore breath analysis 
for marijuana detection specifically. Several publications have expanded the 
available knowledge of THC and its metabolites’ concentrations in both breath 
and air [51, 52] from smoking and passive smoking studies.  
Previous studies have determined the relationship between THC breath 
concentrations and windows of detection after smoking. Research by Valentine 
and associates were the first to examine the presence of THC in breath after 
cannabis smoking in 1979. Using a polyethylene foam wafer breath entrapment 
device followed by solvent extraction and High Performance Liquid 
Chromatography – Mass Spectrometry (HPLC-MS) analysis an average 
concentration (n=6) of 11.2 ± 6.21 ng of THC in breath was detected 1 to 2 hours 
after smoking [58]. A 1983 study by Manolis and colleagues compared THC 
contaminated breath by Tenax® sorbent tube and solvent collection methods 20 
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minutes after cannabis smoking. The Tenax® desorption method by GC/MS 
obtained the highest concentration (n=1) of THC in breath at 8.1 ng before 
correction for losses, which was double that absorbed for the solvent method 
[55]. Despite the previously demonstrated benefits of thermal extraction using 
tenax® sorbent tubes, the more recent studies of cannabis user breath were 
achieved by solvent extraction of breath samples collected onto filter pads, 
followed by liquid chromatography analysis. In 2011, Beck and associates 
reported detectable levels of THC in breath following 1 (n=7) and 12 (n=1) hours 
after smoking at 180-773 pg and 90 pg, respectively. In 2013, Himes and 
associates classified detection windows by occasional and chronic marijuana 
smokers. Occasional marijuana smokers had a narrower detection time of 0.5-2 
hrs with a median range (n=11) of 61.0 pg per filter pad of THC detected, 
compared to chronic marijuana smokers who had a detection window of 0.5-4 hrs 
with a median range (n=13) of 94.8 pg per filter pad of THC detected [57].  
1.2 Nicotine Breath Detection 
Studies of nicotine detection in urine [67], sweat and saliva [68] have been 
used for therapeutic applications of health insurance screening and smoking 
cessation programs [69]. Nicotine detection in breath has been considered in 
environmental applications investigating environmental tobacco smoke (ETS) 
and its impact on air quality of enclosed spaces [70]. The harmful constituents of 
tobacco smoke [71] and electronic cigarette (e-cig) vapor [72] are publicly 
reported and efforts measuring their concentrations for occupational workplace 
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ETS exposures [45, 73] have previously been examined using well developed 
sorbent based sampling and thermal desorption analytical techniques [43].   
Environmental tobacco smoke pollution is the result of second hand and 
third hand smoking. Second hand smoking is characterized by mainstream 
smoke inhaled and subsequently exhaled by the smoker and sidestream smoke 
of the burning cigarette [70]. Third hand smoking is characterized by residue 
desorption of tobacco related VOCs absorbed into cushions, curtains, clothing or 
from a smoker’s breath after smoking has ceased [34]. Popularization of 
alternative electronic smoking apparatus’ has involved additional contributors to 
ETS, including e-cig vapor. These studies often research the differences in 
cigarette smoke inhalation and exhalation using nicotine as an exposure indicator 
for ETS. Feng and associates studied the Inhalation pattern of 16 smokers to 
determine the respiratory retention of nicotine while smoking 6 cigarettes each 
day for 4 days using Cambridge filter pads for collection and GC/MS analysis. 
The nicotine concentration of exhaled smoker breath after no smoke inhalation, 
normal smoke inhalation, and deep inhalation was respectively 1.015 ± 0.256 
mg/cig, 0.019 ± 0.014 mg/cig, and 0.004 ± 0.002 mg/cig [54]. These 
investigations of nicotine concentrations in exhaled mainstream smoke [54, 74] 
are not to be confused with investigations of exhaled breath after smoking. 
As smoking habits of individuals strongly influence their exhaled breath 
[28, 35, 75] have been able to demonstrate that nicotine is detectable in breath 
following tobacco smoking. Research by Ding and associates in 2009 analyzed 
12 breath measurements of smokers’ breath (n=2) one hour after smoking by 
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extractive electrospray ionization coupled to a linear trap quadrupole mass 
spectrometer (EESI-LTQ-MS) to determine nicotine concentrations of 5.8-7.6 
pg/ml [76]. Research by Berchtold and colleagues investigating appropriate mass 
analyzers and ionization technology for narcotic breath detection were unable to 
confirm detectable nicotine levels with extractive electrospray ionization coupled 
to a quadrupole time of flight mass spectrometry (EESI-Q-TOF-MS) technology. 
However, analysis in this research of exhaled breath after smoking of a single 
cigarette by atmospheric pressure chemical ionization coupled to quadrupole 
time of flight mass spectrometry (APCI Q-TOF) was able to detect a 
concentration of 6.2 ± 0.9 pg/ml of nicotine after 70 minutes [62]. The more 
recent nicotine exhaled breath studies considered detection after smoking of low 
dose cigarettes as well as rechargeable e-cigarettes. Research by Marc and 
associates detected nicotine concentrations of 7 µg/m3 and 1 µg/m3 for cigarette 
and e-cig smokers respectively 30 minutes after smoking by tenax® sorbent tube 
sampling and GC/MS analysis [33].  Real time nicotine exhaled breath analysis 
by PTR-MS detected nicotine concentrations of 1150 ppb and 7 ppb for cigarette 
and e-cig respectively after a single exhalation [24, 77]. These research studies 
examining nicotine concentration during particular detection windows depend on 
the available amount of nicotine for exhalation. 
2.0 Toxicokinetics of Nicotine in Breath Analysis 
Breath analysis literature has demonstrated that inhaled drugs can be 
identified in exhaled breath within an appropriate detection window based on the 
	48 
	
drugs’ toxicokinetics. Toxicokinetics involves the processes of absorption, 
distribution, biotransformation and excretion. The toxicokinetic process of 
nicotine in breath analysis will be reviewed. 
2.1 Absorption  
Nicotine among many of the other 7,000 chemicals contained in cigarette 
smoke [70, 71] enter the body by route of the mouth when an individual smokes. 
The two-phase smoking action includes the drawing of cigarette mainstream 
smoke into the mouth during the puff of a cigarette and inhaling the smoke into 
lungs where it is held and mixed then exhaled [78]. The absorption and retention 
of nicotine as it is inhaled into the respiratory system undergoes two main 
mechanisms of deposition dependent on the chemical form of nicotine. The two 
main deposition mechanisms are evaporative gas deposition and particle 
deposition with evaporation from the vapor phase [79]. 
In tobacco smoke, nicotine is available in one of two forms depending on 
the pH of its solution [71, 80]. The unprotonated (lipophilic) free base form 
favored in basic conditions is semi-volatile and present in gas phase, while the 
protonated (hydrophilic) form favored in acidic conditions is nonvolatile and 
present in the particulate phase [71, 79]. Within the tobacco plant leaves, nicotine 
largely exists in its protonated form [71] and is transferred when inhaled into the 
body from mainstream smoke on tar droplets, identified as particulate matter [79, 
81]. Any unprotonated nicotine in the particulate matter of the cigarette smoke 
can volatize out into the gas phase, where it undergoes rapid deposition in the 
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respiratory tract and readily passes into lipid membranes [71, 80]. Evaporation of 
nicotine from the particle to the vapor phase contributes to a higher percentage 
of unprotonated nicotine presence in the inhaled puff of cigarette smoke. 
However, evaporation has saturation limitations and not all nicotine in particulate 
matter can evaporate without dilution [79].   
Nicotine retention in the lung and airways is additionally dependent on the 
particular smoking device and chemical concentration in the inhaled smoke [70]. 
Concentrations of commercial tobacco products range from 6-18 mg/g per 
cigarette [71, 81, 82]. Cigars have been reported to have half the concentration 
of cigarette tobacco [80]. While e-juice liquids can vary in nicotine solutions of 3-
100 mg/ml concentrations.  
Nicotine retention studies from cigarette smoking reported an 80-92% rate 
[74, 81]. Research on e-cig vapor absorption examined by inhalation and mouth 
hold patterns reported an 86% and >99% retention rate of nicotine delivered into 
the mouth and lung, respectively [83]. Nicotine mouth retention for a mild cigar 
was an average of 48%, and an average of 58% for a strong cigar [78].  
2.2 Distribution 
The distribution of a drug through the body occurs after absorption into the 
respiratory system. Respiratory system includes an upper and lower airway 
system and a gas exchange system [84]. As illustrated in Figure 16, the lower 
airway system is covered with a thin surface liquid, called the epithelial lining fluid 
(ELF). In the ELF, drugs must diffuse across the alveolar epithelium, the fluid in 
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the interstitial space and the capillary wall [84]. The drug can then enter the blood 
stream where it is further distributed. Factors that influence the passage of drugs 
into the ELF include protein binding, molecular weight, and lipophilicity [84]. The 
unprotonated form of nicotine is lipophilic and thus rapidly diffuses across the 
lung membranes for distribution into brain and heart tissues [79, 80, 82]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Schematic of a single alveoli of the alveolar capillary system showing 
the gas and molecule exchange.  
2.3 Biotransformation 
Metabolism after distribution of nicotine through the blood stream occurs 
primarily in the liver with secondary metabolism occurring in the lung and kidney 
[81, 82]. The predominant metabolite of nicotine is cotinine. In most people, 70% 
to 80% of nicotine is metabolized to cotinine by C-oxidation [70, 81]. 
2.4 Excretion  
Although nicotine primarily undergoes renal excretion, it is also available 
for excretion through exhaled breath. Nicotine has a clearance half-life of 1.9 hrs 
from the trachea-bronchial region of the lung [78]. Nicotine is available for 
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excretion in exhaled breath because during the absorption process of nicotine 
diffusion into the surface fluid of the epithelium, some of the nicotine vapors are 
lost [79]. Given this information regarding the availability of nicotine in exhaled 
breath, studies were able to detect nicotine in breath 20 minutes [28] and even 
70 minutes [62] after smoking dosages by cigarette. Even the metabolite cotinine 
has been reported as detectable in exhaled breath 1 hour after nicotine dosage 
by cigarette [76].
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CHAPTER 5: BREATH ANALYSIS OF SMOKERS USING CMV-GC/MS 
The experimental design implementing the newly proposed CMV method 
for exhaled breath collection for discrimination of smoker and nonsmoker breath 
by target analyte nicotine is described within this chapter.   
1.0 Subjects 
Ethical approval for human studies was obtained from the Institutional 
Review Board (IRB) (No 2015/0157) at Florida International University (FIU). The 
recruitment of study subjects on FIU campus was opened to individuals of ages 
18 to 66 who participated in any type of smoking (i.e., cigarette, e-cigarette, 
cigar, hookah, etc.). Informational flyers posted around campus as well as in 
person soliciting assisted in the recruitment of participants. Upon completion of 
recruitment, 13 self-declared smokers and 7 nonsmokers control gave their 
written consent to participate in the study. It was determined that 84.6% of 
smokers were between the ages of 18-25 with the remaining 15.4% between the 
ages of 26-35 years old. 71.4% of the nonsmoking control participants were 
between the ages of 18-25 with the remaining 28.6% between the ages of 26-35 
years old. To account for variation between subjects, participants were surveyed 
via a questionnaire to obtain demographic information, smoking habits as well as 
other potential volatile chemical exposure. Questionnaire responses are 
summarized in Table 4. No information on the health status of the participating 
individuals were included in the evaluation of their breath samples. In some 
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cases, food intake prior to sampling was noted, however volunteer diet was not 
considered as a variable in this study.  
Table 4: Description of the demographics of participating subjects. 
 
 
	
	
 
2.0 Materials  
The sampling method using the homemade BCD as described in Chapter 
3, Section 4.1 was utilized in this case study of the exhaled breath collection of 
smokers and nonsmokers. Subjects were given new mouthpieces and previously 
conditioned CMVs. The CMVs were conditioned for 2 hours in an oven at 350˚C 
and blanked to record their baseline background in the instrument before 
sampling. The CMVs were wrapped in foil, labeled and stored in a sealed vial 
before until use. Minor discomfort was reported by some participants as a result 
of the resistance of the 7 mm opening of the BCD.  
3.0 Standard Reagents  
 
Separate experiments of standard compound solutions diluted with MeOH 
were ran under the CMV and liquid injection methods reported in Chapter 3, 
Section 1.0 to determine retention time and mass spectra confirmation of 
compounds identified in exhaled breath samples of smoker and nonsmoker 
control subjects.  
 Smoker Nonsmoker 
18-25 years Male Female 
8 
3 
2 
3 
26-35 years Male Female 
2 
0 
1 
1 
Total Subjects 13 7 
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A total of 32 standard compound solutions were available for retention 
time confirmation. Limonene, α-pinene, β-pinene, dibutyl phthalate, Bisphenol A, 
octadecane, tricosane, cinnamaldehyde, and octanol from Acros Organics in 
New Jersey. Nicotine, benzyl alcohol, pentadecane, 1-methylnapthalene,  
2-methylnapthalene, naphthalene, phenol, undecane, tetradecane, dodecane,  
β-caryophyllene, α-humulene, benzaldehyde, nonanal, eicosane, docosane, 
nonadecane, heneicosane, pristane, and tridecane and from Sigma-Aldrich in 
Missouri. Linalool, indole, and propylene glycol were from Fluka, TCI America 
and Flavor Apprentice, respectively. 
4.0 Sampling Protocol & Method 
The sampling protocol of exhaled breath collection has been previously 
described in Chapter 3, Section 4.2. One different occurrence during recruitment 
of subjects were that the option of an onsite sampling session was offered in 
addition to the opportunity to make an appointment for a later date at the 
laboratory. Laboratory set up of appointment sampling is displayed in Figure 17, 
while the kit for onsite sampling is displayed in Figure 18. Breath sampling 
consisted of the subject performing up to ten prolonged mixed breaths through a 
homemade BCD (Chapter 3, Figure 10, bottom). To detect possible 
environmental contamination during onsite collection, field blank CMVs were 
opened in the sampling location to the environment for passive air sampling 
during the sampling period, then repackaged and analyzed along with other 
samples.  
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Figure 17: Laboratory set up of the sampling area for participants who made 
appointments. Pictured are consent forms, questionnaire, CMVs, tedlar sampling 
bags, pump, mouth piece, timer. 
 
	
Figure 18: Sampling kit taken for onsite breath sample collection. Pictured are 
packets of consent forms and questionnaires. CMVs packaged in vials, mouth 
pieces, connection tubes, and kim wipes. 
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5.0 Results  
5.1 Survey Results 
Thirteen of the twenty-one subjects reported that they had a smoking 
history. Five smokers reported a singular smoking history of only smoking 
cigarettes in their past while the remaining eight smokers reported a history in at 
least two products (i.e., cigarettes, e-cigarettes, cigars, hookah, etc.).  Eleven of 
the smokers reported that they smoked a cigarette before sampling, while two 
others reported smoking an e-cigarette and cigar, respectively. Eleven (84.6%) of 
the smokers reported that they smoked daily, one (7.7%) smoker reported that 
they smoked at least three times a week, and the remaining smoker (7.7%) 
reported that they smoked less than weekly. Those who stated that they smoked 
daily ranged in 1-15 cigarettes a day with an average of 6 ± 3.58 cigarettes. The 
following five brands of cigarettes as detailed in table 8 were reported as being 
the source of nicotine in the breath: Newport, L & M, Camel, American Spirit, and 
Marlboro. 
5.2 Smoker and Nonsmoker Breath Analysis 
Chromatographic profiles of each of the subjects exhaled breath were 
analyzed. Peaks were identified by NIST and WILEY mass spectra library 
matches as well as retention time and mass spectra comparison of a select 
number of standard solutions. The combined total of 119 compounds were 
identified between all subjects’ (n=20) exhaled breath. Those 119 compounds 
consisted of aromatics (17%), alcohols (7%), alkanes (19%), alkenes (3%), 
aldehydes (4%), amines (2%), amides (1%), carboxylic acids (11%), furans (2%), 
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Figure 19: TIC of the exhaled breath profile of subject 27-01, a menthol cigarette smoker, with selected identified 
peaks numbered from Table 9.  
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Figure 20: TIC of the exhaled breath profile of subject 36-01, the e-cigarette smoker, with selected identified peaks 
numbered from Table 9.  
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Figure 21: TIC of the exhaled breath profile of subject 44-01, the cigar smoker, with selected identified 
peaks numbered from Table 9.  
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Figure 22: TIC of the exhaled breath profile of subject 28-00, a nonsmoker, with selected identified peaks numbered 
from Table 9. 
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ketones (4%), monoterpenes (12%), sesquiterpenes (8%) and triterpenes (1%) 
which are described in table 7. Cigarette smokers (n=11) collectively totaled 104 
compounds, the e-cigarette smoker (n=1) totaled of 32 compounds, the cigar 
smoker (n=1) totaled 50 compounds and the nonsmokers (n=7) collectively 
totaled 62 compounds in exhaled breath samples. There were more compounds 
found in smokers than nonsmokers suggesting that smoking contributes a 
greater amount of exogenous compounds to the breath profile. The mean total 
number of compounds identified per smoker subject (i.e., Cigarette, e-cig, cigar) 
was 42 (RSD ±8, range 28 to 52). The mean total number of compounds 
identified per nonsmoker subject was 33 (RSD ±4, range 28 to 40). The exact 
numbers of compounds found per subject are described in table 5. Example total 
ion chromatograms (TIC) of each smoker device type (i.e., cigarette, e-cigarette, 
cigar) and a nonsmoker showing distinct peak patterns are shown in Figures 19, 
20, 21 and 22 respectively plotted on the same scale. The TIC of the cigarette 
smoker exhaled breath was more complex, because of the increased chemical 
components expected in tobacco products as a result of combustion [85, 86]. 
The varying chemical compositions of the exhaled breath from cigarette smokers 
depend on the differences in tobacco blend of the cigarette brands used [71].  
Total of 119 compounds (32 confirmed by standards) were found and 
compared across subjects and between samples with 14 of them present at least  
once in each of the three smoker categories and the nonsmokers. The 14 
identified compounds response in each group are shown in Figure 23.  
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E-cigarette smokers were generally more concentrated in eleven of the 
ubiquitous compounds: nonanal, dodecane, decanal, tetradecane, 3-ethyl-5-(2-
ethylbutyl)-octadecane, tetradecanoic acid, z-7 hexadecanoic acid,                     
n-hexadecanoic acid, isopropyl palmitate, 1-octadecene, and oleic acid. While 
the cigar smoker was more concentrated in indole, and the nonsmokers were 
more concentrated in octadecanoic acid, and isooctyl phthalate. 
Table 5: Total number of compounds found per exhaled breath subject sample. 
Subject	 Identifier	 Number	of	Compounds	
07-01	 S-1	 52	
38-01	 S-2	 48	
08-01	 S-3	 45	
39-01	 S-4	 28	
12-01	 S-5	 36	
29-01	 S-6	 37	
34-01	 S-7	 44	
06-01	 S-8	 41	
27-01	 M-1	 44	
47-01	 M-2	 39	
25-01	 M-3	 52	
36-01	 E-1	 32	
44-01	 C-1	 50	
26-00	 N-1	 40	
46-00	 N-2	 34	
30-00	 N-3	 28	
48-00	 N-4	 31	
21-00	 N-5	 35	
28-00	 N-6	 34	
09-00	 N-7	 32	
S=	Cigarette	Smoker,	M=menthol	cigarette	
Smoker,	E=	electronic	cigarette	smoker,	C=cigar	
smoker,	N=	nonsmoker	
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Figure 23: Visual representation of the 14 ubiquitous compounds found at least once in the four groups: Cigarette 
smokers (dark grey), cigar smokers (white), e-cigarette smokers (black), and nonsmokers (light grey). 
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5.2.1 Smoker Breath Literature Comparison  
Breath analysis research investigating the exhaled breath of smokers and 
nonsmokers have been able to successfully distinguish between the two groups 
as a result of key smoking biomarkers. The significant biomarkers associated 
with cigarette smoking reported in literature are listed in table 6. A few of those 
listed compounds (i.e., acetone, acetonitrile, isoprene, benzene and toluene) 
found in a smokers’ breath are also found in nonsmokers’ breath, but at smaller 
concentrations [34, 36, 37]. A few of the main VOCs identified in healthy breath 
are as follows: methanol, acetaldehyde, acetone, isoprene [37, 41] and ethanol 
[87]. These compounds are identified in both groups as they are endogenous 
compounds resulting from production within the body. For example, isoprene is a 
product of the mevalonic acid pathway of cholesterol synthesis and acetone is a 
product of glucose metabolism [6]. However, the VOCs common to smokers only 
are likely a result of incomplete combustion of organic matter in tobacco products 
[71]. 
Previously reported literature focused on the detection and identification of 
VOCs in exhaled breath and thus reported lists of low molecular weight 
compounds with boiling points between 50-150°C. The current research study 
focused on the specific detection of nicotine in exhaled breath of smokers, and 
thus the experimental method was out of range to detect the majority of 
previously reported compounds in breath including the significant compounds 
associated with smoking. In this research, 11 compounds were found to be 
consistent with literature reporting exhaled breath profiles of smokers. 
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 Table 6: List of compounds significant to exhaled breath of smokers identified in 
literature.  
	
	
	
	
	
	
	
	
	
	
 
Those compounds of the current study identified in smokers are as 
follows: propanoic acid [91], propylene glycol [33], α-pinene [91, 92], β-pinene 
[91, 92], octanal [91], eucalyptol [91, 92], undecane [91, 92], menthone [92], 
nicotine [8, 33, 35, 54], pentadecane [9] and butylated hydroxytoluene [9]. In this 
research, 17 compounds were reported in literature as being consistent with 
exhaled breath profiles of both smokers and nonsmokers. Those compounds 
were phenol [9, 35], limonene [8, 9, 35], γ-terpinene [9, 91], nonanol [8, 9, 33], 
dodecane [8, 9], decanal [8, 9, 33], naphthalene [8, 9], 2-phenoxy-ethanol [9, 91], 
nananoic acid [33], tridecane [8, 9], indole [9], tetradecane [8, 9],  
(Z)-6,10-dimethyl-5,9-undecadien-2-one [9], diethyl phthalate [9], pristine [8], 
octadecane [8], and heneicosane [8]. 
Chemical Class Compound Literature Source 
Aromatic 
Hydrocarbons 
Benzene [25, 27, 34, 36, 41, 88]  
Toluene [25, 27, 34, 36, 40, 41] 
Xylene isomers [27, 36, 40] 
1,3 - cyclohexadiene [41, 90] 
1,3 - cyclopentadiene [27, 41, 90] 
Styrene [36, 90] 
ethylbenzene [36, 90] 
Furan derivatives 
2,5 - dimethylfuran [27, 36, 40, 41, 88, 89] 
Furan [25, 36, 41, 88] 
2 – methylfuran [25, 41 88] 
3 - methylfuran [25, 36, 41, 88] 
Saturated 
Hydrocarbons 
2-methyl-1-butene [41] 
1,4 – pentadiene [41] 
Butadiene [27] 
Pentene [27] 
isoprene [25, 27, 88] 
Unsaturated 
Hydrocarbons 
Butane [27] 
Octane [36] 
Decane [36] 
Nitrile Acetonitrile [25, 36, 34, 41, 88, 90] 
Ketone Acetone [27, 34, 90] 
Alcohol 2-propanol [25] 
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Table 7: Statistical Mann Whitney test results of only the tentatively identified compounds found in >9% of exhaled 
breath profiles of at least one of the groups: cigarette smokers (n=11) and nonsmokers (n=7).  
   Mean Peak Area P-value 
Class 
 
CAS No. Compound 
 
Cigarette 
Smokers  
(n=11) 
Nonsmokers 
(n=7) 
Cigarette 
Versus 
Non- Smokers 
Alcohols 
57-55-6 Propylene glycol 0 0 - 
111-90-0 2-(2-ethoxyethoxy)-ethanol 4.46E+06 2.78E+06 0.53601 
100-51-6 benzyl alcohol 0 4.87E+06 0.65899 
4217-66-7 di-2-phenyl-,1,2-propanediol 4.03E+06 0 0.59615 
617-94-7 α-α-dimethyl benzenemethanol 2.08E+06 8.94E+06 0.15089 
122-99-6 2-phenoxy-ethanol 2.29E+06 4.40E+06 0.32830 
2136-72-3 2-(octadecloxy)-ethanol 6.35E+06 3.34E+06 0.86010 
Aldehydes 
124-19-6 Nonanal 3.08E+07 1.76E+07 0.47894 
124-13-0 Octanal 2.08E+06 0 0.59615 
0.59615 112-31-2 Decanal 4.43E+07 2.99E+07 
104-55-2 cinnamaldehyde 0 0 - 
629-90-3 3-heptadecanal 1.16E+07 4.50E+06 0.10419 
629-90-3 heptadecenal 1.48E+05 5.92E+04 0.86010 
Alkanes 
1120-21-4 Undecane 4.85E+06 0 0.79141 
1632-70-8 5-methyl-undecane  6.46E+05 0 0.79141 
930-02-9 1-(ethenyloxy)-octadecane 1.26E+06 0 0.59615 
112-40-3 Dodecane 7.84E+06 4.35E+06 0.72423 
629-50-5 tridecane 7.89E+06 3.38E+06 0.21091 
4390-04-9 2,2,4,4,6,8,8-heptamethyl-nonane 2.16E+06 1.87E+06 0.42515 
629-59-4 Tetradecane 9.98E+06 4.07E+06 0.01137 
19780-34-8 3-methylene-tridecane 3.48E+06 1.93E+06 0.42515 
55282-12-7 3-ethyl-5-(2-ethylbutyl)-octadecane 5.01E+06 2.66E+06 0.53601 
629-62-9 pentadecane 4.37E+06 0 0.12594 
17312-55-9 3,8-dimethyl-decane 4.91E+06 0 0.37493 
544-76-3 hexadecane 4.81E+06 0 0.59615 
629-78-7 heptadecane 2.07E+06 1.16E+06 0.86010 
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Table 7 (Continued) 
   
Mean Peak Area P-value 
Class  CAS No. 
Compound 
 
Cigarette 
Smokers  
(n=11) 
Nonsmokers 
(n=7) 
Cigarette 
Versus 
Non- Smokers 
Alkanes  
(cont.) 
1921-70-6 pristane  6.25E+06 3.49E+06 1 
593-45-3 octadecane 6.46E+05 6.56E+05 0.92980 
295-65-8 cyclohexadecane 1.19E+07 0 0.12594 
629-92-5 nonadecane 8.31E+05 1.60E+06 0.72423 
112-95-8 eicosane 1.17E+05 0 0.79141 
629-94-7 heneicosane 1.06E+06 4.78E+06 0.86010 
629-97-0 Docosane 5.76E+05 7.30E+06 0.42515 
638-67-5 Tricosane 6.29E+05 6.74E+06 0.01539 
646-313-1 tetracosane 5.45E+05 6.23E+06 0.02677 
629-99-2 pentacosane 8.70E+05 7.37E+06 0.04411 
Alkenes 
34303-81-6 3-hexadecene  1.11E+07 1.31E+06 0.21091 
872-05-9 1-decene 4.32E+06 7.58E+06 0.42515 
112-88-9 1-octadecene 3.58E+06 6.54E+06 0.37493 
Amides 301-02-0 9-octadecenamide 5.18E+05 1.42E+06 0.59615 
Amines 54-11-5 Nicotine 5.46E+06 0 0.00829 7378-99-6 N,N-dimethyloctylamine 2.47E+06 1.78E+05 0.59615 
Aromatics 
108-95-2 Phenol 2.95E+07 3.54E+07 0.65899 
106-46-7 1,4-dichloro-benzene 7.02E+06 0 0.21091 
100-45-8 4-cyanocyclohexene 2.82E+07 2.00E+07 0.37493 
141-93-5 1,3-diethyl benzene 6.81E+06 0 0.79141 
150-76-5 Mequinol 0 0 - 
94-71-3 2-ethoxy-phenol 8.07E+05 0 0.79141 
150-78-7 1,4-dimethoxy-benzene 5.53E+06 0 0.06925 
89-78-1 Menthol 6.94E+08 0 0.37493 
3623-52-7 Isomenthol 2.12E+06 1.49E+06 0.53601 
91-20-3 Napthalene 2.53E+06 7.94E+05 0.59615 
104-45-0 1-methoxy-4-propyl-benzene 0 0 - 
95-16-9 Benzothiazole 3.19E+05 1.11E+06 0.86010 
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Table 7 (Continued) 
 
  Mean Peak Area P-value 
Class  CAS No. 
Compound 
 
Cigarette 
Smokers  
(n=11) 
Nonsmokers 
(n=7) 
Cigarette 
Versus 
Non- Smokers 
Aromatics 
(cont.) 
120-72-9 Indole 2.38E+07 6.91E+06 0.15089 
90-12-0 1-methyl-napthalene 2.76E+06 8.09E+05 0.01539 
91-57-6 2-methyl-napthalene 3.89E+06 1.79E+06 0.24629 
128-37-0 Butylated hydroxytoluene 0 0 - 
88-29-9 7-acetyl-6-ethyl-1,1,4-tetramethyletralin 3.32E+05 0 0.79141 
599-64-4 4-(1-methyl-1-phenylethyl)- phenol 1.22E+06 0 0.79141 
80-05-7 Bisphenol A 2.23E+06 8.34E+05 0.86010 
2882-20-4 2-methyl-3(methylthio)-pyrazine 0 0 - 
Carboxylic 
Acids 
79-09-4 Propanoic Acid 0 0 - 
107-92-6 Butanoic acid 0 1.00E+06 0.65899 
79-31-2 2-methyl-2-propenoic acid 0 0 - 
124-07-2 Octanoic acid 1.98E+06 3.70E+06 0.86010 
112-05-0 nonanoic acid 3.63E+06 5.80E+06 0.37493 
143-07-7 Dodecanoic Acid 1.47E+07 1.89E+07 0.72423 
544-63-8 Tetradecanoic Acid 1.11E+07 2.21E+07 0.17911 
1002-84-2 Pentadecanoic acid 3.87E+06 7.67E+06 0.42515 
2416-19-5 Z-7-Hexadecanoic acid 6.40E+06 2.07E+07 0.06925 
57-10-3 n-Hexadecanoic acid 5.83E+07 9.22E+07 0.12594 
112-80-1 oleic acid 9.25E+06 9.72E+06 1 
693-72-1 Vaccenic acid 0 1.43E+07 0.37493 
57-11-4 Octadecanoic acid 2.81E+07 4.01E+07 0.21091 
Esters 
103-11-7 2-ethylhexyl acrylate 1.04E+07 5.65E+05 0.02042 
109-21-7 Butyl butylate 1.35E+06 0 0.37493 
84-66-2 Diethyl Phthalate 2.40E+07 1.87E+07 0.53601 
120-51-4 benzyl benzoate 2.75E+06 0 0.37493 
110-27-0 Isopropyl Mysitate 1.81E+06 6.31E+06 0.02677 
84-74-2 dibutyl phthalate 3.81E+06 1.98E+06 0.24629 
142-91-6 Isopropyl Palmitate 1.09E+07 1.09E+07 0.72423 
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Table 7 (Continued) 
 
  Mean Peak Area P-value 
Class  CAS No. 
Compound 
 
Cigarette 
Smokers  
(n=11) 
Nonsmokers 
(n=7) 
Cigarette 
Versus 
Non- Smokers 
Esters 
(cont.) 
27554-26-3 Isooctyl phthalate 2.05E+06 4.08E+06 0.21091 
5444-75-7 2-ethylhexyl ester benzoic acid 3.51E+06 0 0.59615 
102-20-5 2-phenylethyl ester  Benzeneacetic acid 5.13E+05 0 0.79141 
5466-77-3 Octyl methoxy cinnamate 5.95E+05 0 0.59615 
Furans 494-90-6 Menthofuran 1.04E+06 0 0.79141 632-15-5 3,4-diethyl-thiopene 0 0 - 
Ketones 
409-02-9 6-methyl-5-hepten-2-one 9.43E+06 4.51E+06 0.59615 
10458-14-7 Menthone 1.00E+06 0 0.79141 
1937-54-8 Solanone 1.16E+07 0 0.00829 
104-67-6 5-heptyldihydro-2(3H)-Furanone 0 6.04E+05 0.65899 
3796-70-1 (Z)-6,10-dimethyl - 5,9-undecadien-2-one 2.98E+07 1.75E+07 0.65899 
Monoterpenes 
80-56-8 α-pinene 1.14E+07 0 0.37493 
123-35-3 β-myrcene 4.68E+07 0 0.00829 
127-91-3 β-pinene 9.03E+06 0 0.37493 
99-83-2 α-phellandrene 2.51E+06 0 0.59615 
527-84-4 o-cymene 3.07E+06 0 0.59615 
138-86-3 Limonene  2.38E+08 7.85E+06 0.00119 
470-82-6 Eucalyptol 4.56E+07 0 0.59615 
99-85-4 γ-Terpinene 2.19E+07 1.33E+06 0.32830 
99-86-5 α-Terpinene 3.90E+06 0 0.21091 
78-70-6 Linalool 0 0 - 
673-84-7 (4E,6Z) – allo-ocimene 1.47E+06 0 0.59615 
76-22-2 Menthacamphor 4.24E+05 0 0.79141 
106-22-9 Citronellol 4.44E+06 0 0.79141 
5392-40-5 Citral 5.47E+06 0 0.00829 
2623-23-6 Menthyl Acetate 4.91E+07 0 0.59615 
Sesquiterpenes 515-69-5 α-bisabolol 2.74E+05 0 0.79141 512-61-8 α-Santalene 1.06E+06 0 0.59615 
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Table 7 (Continued)    
 
Mean Peak Area P-value 
Class  Identifier Compound 
Cigarette 
Smokers  
(n=11) 
Nonsmokers 
(n=7) 
Cigarette 
Versus 
Non- Smokers 
Sesquiterpenes 
(Cont.) 
87-44-5 β-Caryophyllene 2.11E+07 4.39E+06 0.86010 
18797-84-8 β-Farnesene 1.67E+06 0 0.79141 
6753-98-6 α-humulene 5.60E+06 0 0.59615 
109119-91-7 Aromadedrene 1.52E+06 0 0.79141 
177066-67-0 β-Selinene 2.54E+06 0 0.59615 
88-84-6 β - guaiene 7.96E+05 0 0.79141 
489-29-2 β-Maaliene 1.22E+06 0 0.79141 
6813-21-4 Selina-3,7(11)-diene 3.78E+06 3.66E+05 0.86010 
Triterpenes 7683-64-9 Squalene 0 0 - 
Compounds are organized by their chemical class. 
P-values of significant compounds are bolded and italicized. 
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5.3 Nicotine Quantitation in Smoker Breath Samples 
Peaks tentatively identified as nicotine in the exhaled breath profiles of 
smokers were similar in retention time (8.732 min) and mass spectra to those 
observed in the chromatograms of nicotine liquid standards spiked on the CMV. 
The target ion 84 m/z and 133 and 162 m/z qualifier ions of nicotine were 
selected for ion monitoring of exhaled breath samples as observed in sample of 
subject 27-01 in Figure 24. Nicotine in breath was quantified from the linear 
standard curve (R2= 0.9806) as seen in Figure 7 of Section 2.0.1 in Chapter 3. 
The nicotine mass extracted from the exhaled breath of the smokers are reported 
in table 8. Nicotine was detected in 9/13 (69%) of smoker exhaled breath. The 
relationship between nicotine concentration smoke frequency and sampling time 
since smoking session ended was not considered in this study. 
	
Figure 24: Chromatogram of the extracted ions of nicotine identified in the 
exhaled breath sample of subject 27-01 at RT= 8.730 min. Presence of m/z ions 
84 (line), 133 (dashed line), and 162 (dotted line) confirm nicotine in the sample. 
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Table 8: Smokers self-reported questionnaire responses describing smoking 
habits and quantified nicotine response. 
 
 
Figure 25: Overlay SIM chromatograms over the retention range 8.7-8.8 minutes 
for e-cigarette smoker subject 36-01(dashed line), cigar smoker subject 44-
01(line), and cigarette smoker subject 08-01 (dotted line). Peak of nicotine in the 
respective exhaled breath samples shown at 8.745 min. 
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E-cig Smoker Cigar Smoker Cigarette Smoker
Subject 
ID 
Smoke 
Frequency Smoke Product 
Time 
since 
Smoked 
Absolute 
Mass 
Extracted 
39-01 Less than Weekly Newport cigarette 4 min 
n.d.ǂ 
38-01 8 times daily L&M cigarette 15 min 130 pg 
12-01 4 times daily Camel cigarette 10 min n.d.ǂ 
36-01 7-10 times daily E-cigarette 20 min 
552 pg 
27-01 4 times daily American Spirit Menthol cigarette 5 min 
208 pg 
06-01 More than 3 times a week Marlboro cigarette 60 min 
142 pg 
08-01 10-15 times daily Newport cigarette 10 min 
131 pg 
29-01 Twice daily Marlboro Red cigarette 10 min n.d.ǂ 
07-01 7 times daily Marlboro Red cigarette 5 min 149 pg 
34-01 8 times daily Marlboro Gold Light cigarette 20 min 
131 pg 
25-01 Once a day Newport cigarette 2 min 113 pg 
44-01 3 times a day Drew Estate Cigar 30 min 201 pg 
47-01 7 times a day Newport Red cigarette 3 min n.d.ǂ 
n.d. ǂ = nicotine not detected 
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For cigarette smokers the average amount of nicotine detected was 143 ± 
31 pg, compared to 201 pg for a cigar and 552 pg from the e-cigarette. An 
overlay of the nicotine SIM TIC peaks of an e-cig, cigar and cigarette response 
are shown in Figure 25. Comparison of the detected nicotine concentrations in 
the tobacco cigarettes and e-cigarette are not in agreement with previous 
literature. It is expected that nicotine emissions from tobacco based products 
should be more than those of e-cigs [24, 77, 86, 93]. Nicotine emission differs by 
e-cig brand and solution concentrations. The e-cig user of this study smoked 
from an open system e-cig device that can be refilled, however the solution 
concentration used was not disclosed in the self-reported survey. Provided the 
heavily concentrated nicotine e-cig solutions available, it seems fair to assume 
that there could be an instance where the nicotine emission of an e-cig would be 
higher than emissions of a cigarette given a high enough concentration.  
5.4 Statistical Analysis of Breath Samples 
 
Multiple statistical analyses were applied to the data. The statistical 
difference within the treatment groups of the three smoker device types cigarette, 
e-cigarette and cigar was examined using the Freidman test and peak areas, 
where the devices were significant at a p value of 7.517E-06 for an α value of 
0.05. The Freidman test is a non-parametric test equivalent to the parametric 
repeated measures one-way ANOVA, which is used to detect difference in 
treatments across multiple test attempts. This significance between smoker 
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device type is expected as different brands and devices will have different 
ingredients.  
Although there was a significant difference within smoker devices, the 
Freidman test of the smoker types versus the control only determined significant 
differences between the cigarette smoker and nonsmoker breath profiles and not 
the cigar or e-cigarette smokers. Of the cigarette device type there were 
possibilities of regular cigarettes as well as menthol flavored cigarettes. Using the 
Wilcoxon Rank test no significant difference was observed between the two at a 
p value of 0.4026 for an α value of 0.05. 
Determination of statistically significant compounds in the exhaled breath 
samples of the smoker to the nonsmokers were examined by the Mann-Whitney 
Exact test. Mann-Whitey Exact test is the non-parametric equivalent of the 
independent samples t test. Smoker device types of e-cigarette and cigar were 
excluded from the analysis because of limited sample size for the statistical test. 
Each cigar and e-cigarette smoker groups only had one subject, which would 
result in a Mann-Whitney Exact test of low statistical power making it difficult to 
conclude any significant differences. A 9% rule was applied to the cigarette 
smokers where only compounds present in at least 9% of one of the groups (i.e., 
cigarette smoker or nonsmoker) were used in the statistical analysis. After 
applying the rule, the data set contained 18 samples (11 cigarette smokers and 7 
nonsmokers) and 108 compounds of the 119 total. A P value < 0.05 was 
considered significant. P values of the Mann-Whitney exact test identifying 
significant compounds between cigarette smokers and nonsmokers are reported 
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in Table 7. Twelve compounds were determined to be significant between 
cigarette smokers and nonsmokers as follows: β-myrcene, limonene,                 
2-ethylhexyl acrylate, citral, 1-methyl-napthalene, solanone, nicotine, 
tetradecane, isopropyl mysitate, tricosane, pentacosane, and tetracosane. These 
compounds suggest significance for a smoking habit as some have been 
identified as common tobacco flavoring agents and some pyrolysis products. 
5.5 Principal Component Analysis of Breath Samples 
 
Visualization of the compounds found in the exhaled breath samples of all 
subjects was statistically analyzed by principal component analysis (PCA). The 
data set of the PCA consisted of 20 samples and a collective integrated peak 
area of 119 compounds from TICs as listed in Table 9. Not all the compounds 
were present in all of the measured samples, and thus the original data consisted 
of many zero values. JMP (Cary, NC, USA) software were used for the statistical 
analysis. In PCA the first principle component is constructed in the direction of 
the highest variance in the data. The closer points are to one another, the more 
similar profile they have. The 3D PCA score plot in Figure 26 (top) shows a 
summary of all data points between all subjects for the comparisons of all 
smokers to nonsmokers. Generalized groupings were manually drawn by colored 
circles. The single e-cigarette smoker ( ) was distinguishable from the non-
menthol flavored tobacco cigarette smokers (r), and cigar smoker () indicated 
by yellow circle. The menthol flavored cigarette smoker (p) had a distinct 
separation from the traditional cigarette smokers indicated by a black circle.  
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Table 9: Summary of the tentative identification of the VOCs and NVOCs in the exhaled breath samples of 20 total 
subjects: 13 smokers and 7 nonsmokers listed in their elution order. Thirty-two compounds labeled “S” have been 
identified by certified standard solutions and library match, while the remaining compounds label “L” are identified by 
library match only. Compounds are numbered as identified in exhaled breath sample chromatograms. 
  
No. Compound  
Proportion 
of  
Cigarette 
Smokers 
Proportion 
of  
E-Cigarette 
Smokers 
Proportion 
of  
Cigar 
Smokers 
Proportion of  
Nonsmokers 
Confirmation 
Method 
Match 
Quality
 % 
1 Propanoic Acid 0/11 0/1 1/1 0/7 L 46% 
2 Propylene glycol 0/11 1/1 0/1 0/7 S 72% 
3 Butanoic acid 0/11 1/1 0/1 1/7 L 43% 
4 2-methyl-2-propenoic acid 0/11 0/1 1/1 0/7 L 81% 
5 α-pinene 6/11 0/1 0/1 0/7 S 80% 
6 phenol 9/11 0/1 1/1 5/7 S 86% 
7 6-methyl-5-hepten-2-one 5/11 0/1 1/1 2/7 L 86% 
8 B-myrcene 8/11 0/1 1/1 0/7 L 90% 
9 β-pinene 3/11 0/1 0/1 0/7 S 97% 
10 2-(2-ethoxyethoxy)-ethanol 4/11 0/1 0/1 1/7 L 80% 
11 octanal 2/11 0/1 0/1 0/7 L 45% 
12 α-phellandrene 2/11 0/1 0/1 0/7 L 86% 
13 1,4-dichloro-benzene 4/11 0/1 0/1 0/7 L 98% 
14 4-cyanocyclohexene 4/11 0/1 1/1 6/7 L 96% 
15 o-cymene 2/11 0/1 0/1 0/7 L 95% 
16 1,3-diethyl benzene 1/11 0/1 0/1 0/7 L 9% 
17 Limonene  11/11 0/1 1/1 2/7 S 80% 
18 benzyl alcohol 0/11 1/1 0/1 1/7 S 98% 
19 Eucalyptol 2/11 0/1 0/1 0/7 L 96% 
20 γ-Terpinene 5/11 0/1 0/1 2/7 L 90% 
21 α-Terpinene 4/11 0/1 0/1 0/7 L 86% 
22 di-2-phenyl-,1,2-propanediol 2/11 0/1 0/1 0/7 L 72% 
23 α-α-dimethyl benzenemethanol 1/11 0/1 0/1 4/7 L 93% 
24 Mequinol 0/11 1/1 1/1 0/7 L 93% 
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Table 9 (Continued)       
No. Compound  
Proportion 
of  
Cigarette 
Smokers 
Proportion 
of  
E-Cigarette 
Smokers 
Proportion 
of  
Cigar 
Smokers 
Proportion of  
Nonsmokers 
Confirmation 
Method 
Match 
Quality
 % 
25 undecane 1/11 0/1 0/1 0/7 S 95% 
26 5-methyl-undecane  1/11 0/1 0/1 0/7 L 45% 
27 Linalool 0/11 1/1 0/1 0/7 S 91% 
28 Nonanal 11/11 1/1 1/1 6/7 S 97% 
29  (4E,6Z) – allo-ocimene 2/11 0/1 0/1 0/7 L 92% 
30 2-ethoxy-phenol 1/11 1/1 0/1 0/7 L 55% 
31 Octanoic acid 3/11 0/1 0/1 2/7 L 76% 
32 1-(ethenyloxy)-octadecane 2/11 0/1 0/1 0/7 L 72% 
33 Menthone 1/11 0/1 1/1 0/7 L 96% 
34 1,4-dimethoxy-benzene 6/11 0/1 0/1 0/7 L 94% 
35 Menthofuran 1/11 0/1 0/1 0/7 L 87% 
36 Menthacamphor 1/11 0/1 0/1 0/7 L 70% 
37 2-methyl-3(methylthio)-pyrazine 0/11 1/1 0/1 0/7 L 95% 
38 Menthol 3/11 0/1 0/1 0/7 L 91% 
39 Isomenthol 5/11 0/1 1/1 2/7 L 91% 
40 Dodecane 8/11 1/1 1/1 7/7 S 96% 
41 Decanal 9/11 1/1 1/1 7/7 L 81% 
42 Napthalene 3/11 0/1 0/1 1/7 S 95% 
43 1-methoxy-4-propyl-benzene 0/11 1/1 1/1 0/7 L 76% 
44 2-ethylhexyl acrylate 8/11 0/1 1/1 1/7 L 86% 
45 6-octen-1-ol, 3,7-dimethyl 1/11 0/1 0/1 0/7 L 96% 
46 2-phenoxy-ethanol 5/11 0/1 1/1 4/7 L 90% 
47 3,4-diethyl-thiopene 0/11 1/1 0/1 0/7 L 72% 
48 Benzothiazole 1/11 0/1 1/1 1/7 L 15% 
49 nonanoic acid 2/11 0/1 1/1 4/7 L 72% 
50 citral 8/11 0/1 0/1 0/7 L 94% 
51 cinnamaldehyde 0/11 1/1 0/1 0/7 S 98% 
52 tridecane 9/11 1/1 0/1 5/7 S 92% 
53 Menthyl Acetate 2/11 0/1 1/1 0/7 L 91% 
54 Indole 9/11 1/1 1/1 6/7 S 95% 
55 1-methyl-napthalene 10/11 0/1 0/1 5/7 S 95% 
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Table 9 (Continued)       
No. Compound  
Proportion 
of  
Cigarette 
Smokers 
Proportion 
of  
E-Cigarette 
Smokers 
Proportion 
of  
Cigar 
Smokers 
Proportion of  
Nonsmokers 
Confirmation 
Method 
Match 
Quality
 % 
56 2,2,4,4,6,8,8-heptamethyl-nonane 5/11 1/1 0/1 1/7 L 58% 
57 2-methyl-napthalene 9/11 0/1 0/1 5/7 S 91% 
58 Solanone 8/11 0/1 1/1 0/7 L 95% 
59 Nicotine 7/11 1/1 1/1 0/7 S 93% 
60 2(3H)-Furanone, 5-heptyldihydro- 0/11 1/1 0/1 1/7 L 78% 
61 butyl ester butanoic acid 3/11 0/1 0/1 0/7 L 59% 
62 3-methylene-tridecane 5/11 1/1 0/1 1/7 L 78% 
63 Tetradecane 11/11 1/1 1/1 7/7 S 97% 
64 3-ethyl-5-(2-ethylbutyl)-octadecane 6/11 1/1 1/1 3/7 L 58% 
65 3-heptadecanal 10/11 0/1 1/1 5/7 L 62% 
66 α-Santalene 2/11 0/1 0/1 0/7 L 78% 
67 β-Caryophyllene 2/11 0/1 0/1 1/7 S 99% 
68 (Z)-6,10-dimethyl - 5,9-undecadien-2-one 6/11 0/1 1/1 5/7 L 90% 
69 β-Farnesene 1/11 0/1 0/1 0/7 L 94% 
70 3-hexadecene  6/11 0/1 1/1 2/7 L 98% 
71 1-decene 3/11 0/1 0/1 4/7 L 86% 
72 α-humulene 2/11 0/1 0/1 0/7 S 97% 
73 pentadecane 5/11 0/1 1/1 0/7 S 80% 
74 Butylated hydroxytoluene 0/11 0/1 1/1 0/7 L 91% 
75 Aromadedrene 1/11 0/1 0/1 0/7 L 92% 
76 β-Selinene 2/11 0/1 0/1 0/7 L 98% 
77 2-(octadecloxy)-ethanol 3/11 0/1 1/1 2/7 L 93% 
78 β - guaiene 1/11 0/1 0/1 0/7 L 70% 
79 Dodecanoic Acid 6/11 0/1 0/1 7/7 L 96% 
80 β-Maaliene 1/11 0/1 0/1 0/7 L 74% 
81  3,8-dimethyl-decane 3/11 0/1 1/1 0/7 L 70% 
82 Selina-3,7(11)-diene 2/11 0/1 0/1 1/7 L 99% 
83 hexadecane 2/11 0/1 0/1 0/7 S 70% 
84 Diethyl Phthalate 9/11 0/1 1/1 7/7 L 98% 
85 Squalene 0/11 1/1 0/1 0/7 L 94% 
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Table 9 (Continued)       
No. Compound 
Proportion 
of  
Cigarette 
Smokers 
Proportion 
of  
E-Cigarette 
Smokers 
Proportion 
of  
Cigar 
Smokers 
Proportion of  
Nonsmokers 
Confirmation 
Method 
Match 
Quality
 % 
86 heptadecane 2/11 0/1 0/1 2/7 S 91% 
87 pristane  4/11 0/1 1/1 4/7 S 91% 
88 α-bisabolol 1/11 0/1 0/1 0/7 L 87% 
89 2-ethylhexyl ester benzoic acid 2/11 0/1 1/1 0/7 L 64% 
90 Tetradecanoic Acid 8/11 1/1 1/1 7/7 L 98% 
91 benzyl benzoate 3/11 1/1 0/1 0/7 L 98% 
92 octadecane 2/11 0/1 1/1 1/7 S 64% 
93 Isopropyl Mysitate 5/11 0/1 0/1 7/7 L 64% 
94 cyclohexadecane 5/11 0/1 0/1 0/7 L 98% 
95 Pentadecanoic acid 7/11 0/1 1/1 5/7 L 99% 
96 7-acetyl-6-ethyl-1,1,4-tetramethyletralin 1/11 0/1 0/1 0/7 L 99% 
97 phenol, 4-(1-methyl-1-phenylethyl)- 1/11 0/1 0/1 0/7 L 94% 
98 nonadecane 2/11 0/1 0/1 2/7 S 98% 
99 Z-7-Hexadecanoic acid 7/11 1/1 1/1 7/7 L 99% 
100 Benzeneacetic acid, 2-phenylethyl ester 1/11 0/1 0/1 0/7 L 78% 
101 n-Hexadecanoic acid 10/11 1/1 1/1 7/7 L 99% 
102 dibutyl phthalate 7/11 0/1 0/1 2/7 S 55% 
103 eicosane 1/11 0/1 0/1 0/7 S 95% 
104 Isopropyl Palmitate 11/11 1/1 1/1 6/7 L 91% 
105 heptadecenal 2/11 0/1 0/1 1/7 L 59% 
106 1-octadecene 9/11 1/1 1/1 3/7 L 98% 
107 heneicosane 7/11 0/1 1/1 4/7 S 98% 
108 N,N-dimethyloctylamine 3/11 0/1 1/1 1/7 L 80% 
109 oleic acid 8/11 1/1 1/1 4/7 L 99% 
110 Vaccenic acid 0/11 0/1 0/1 2/7 L 98% 
111 Octadecanoic acid 10/11 1/1 1/1 7/7 L 99% 
112 Docosane 5/11 1/1 0/1 4/7 S 97% 
113 Bisphenol A 2/11 0/1 1/1 1/7 S 98% 
114 Tricosane 5/11 0/1 1/1 7/7 S 95% 
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Table 9 (Continued)       
No. Compound 
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of  
Cigarette 
Smokers 
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of  
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Smokers 
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of  
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Nonsmokers 
Confirmation 
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Quality
 % 
115 2-propenoic acid, 3-(4-methoxyphenyl)- 2-ethylhexyl ester 2/11 0/1 0/1 0/7 L 98% 
116 9-octadecenamide 2/11 0/1 0/1 2/7 L 91% 
117 tetracosane 5/11 0/1 1/1 7/7 L 98% 
118 pentacosane 6/11 0/1 1/1 7/7 L 35% 
119 Isooctyl phthalate 9/11 1/1 1/1 7/7 L 59% 
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Figure 26: PCAs of the 119 compounds from the 20 exhaled breath profiles. 
Symbols represented as follows: e-cigarette smoker ( ),cigarette smokers 
(r),menthol cigarette smoker (p), cigar smoker () and Nonsmokers (¢). (Top) 
n=20 subjects (Bottom) n =15 subjects. 
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Nonsmokers (¢) were tightly clustered together with some overlap from smokers 
where nicotine was not detected indicated by green circle. An additional 3D score 
plot of 15 samples of only non-menthol flavored cigarette smokers and 
nonsmokers is shown in Figure 26 (bottom) displaying a more apparent 
separation of the groupings. The misclassification of smokers as nonsmokers 
when nicotine was not detected, demonstrated the possibility of false negatives. 
In addition to the lack of the detection of nicotine, the three smokers misclassified 
also did not detect six of the other significant smoker compounds as follows:      
β-myrcene, citral, solanone, tricosane, pentacosane, and tetracosane. 
6.0 Discussion 
The analyses of the compounds of the exhaled breath profiles in this study 
were interpreted without consideration of inspired air contamination. Some breath 
analysis studies consider the alveolar gradient principle in their analysis. 
Researcher Michael Phillips describes the alveolar gradient principle as 
subtracting the AUC of VOCs in the air from the AUC of VOCs in the breath [8]. 
By this principle positive gradients would indicate endogenous compounds while 
negative gradients would indicate compounds derived from the environment [9, 
50]. The sporadic onsite sampling protocol did not allow for consistent calculation 
of an alveolar gradient because of the imbalance of prepared sampling CMVs 
and available study subjects during a sampling period. To increase recruitment 
opportunities priority of the use of prepared CMVs was given to subject samples 
instead of field blanks if needed. Therefore, field blanks were not consistently 
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taken during sampling. Sampling of the 20 subjects occurred over many 
sampling sessions and in many locations. Differences between locations were 
not considered for this research. 
Field blanks were only taken in three instances. Similar compounds were 
compared between blanks and samples where a small amount of compounds 
found in air were also found in breath. Two examples are shown in Figures 27 
and 28. Figure 27 represents a situation where if the alveolar gradient principle 
was applied, the compounds would all have positive gradients in the samples as 
the AUC response for the field blank was higher than that in the samples. Figure 
28 represents a situation where if the alveolar gradient principle was applied, the 
compounds would all have negative gradients in the samples as the AUC 
response for the field blank was lower than that in the samples. Although efforts 
were made to sample away from the environments with mainstream smoke 
exposure, it is possible that the ambient air may have been contaminated with 
compounds from residual cigarette mainstream smoke as the collection occurred 
near the vicinity of the initial smoking area. These uncontrolled flaws contributed 
to the decision to collectively not apply the alveolar gradient principle in this 
research.  
A lack of alveolar gradient could contribute to exogenous contamination of 
the sample from the contaminated air inhaled. Additional exogenous 
contamination could be a result of contamination from the sampling device or 
from food intake which was not considered in this study. A few of the speculated 
contaminated compounds tentatively identified in the breath samples of this  
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Figure 27: Visual illustration of the comparison of the AUC for the field blank 
(white) taken during the sampling session of subjects 36-01 (light grey) and 44-
01 (black).  
 
Figure 28: Visual illustration of the comparison of the AUC for the field blank 
(black) taken during the sampling session of subjects 06-01 (light grey), 07-01 
(dark grey) and 08-01 (white).  
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research are limonene, cinnamaldehyde, diethyl phthalates, dibutyl phthalate and 
isooctyl phthalates and bisphenol A. 
Limonene and cinnamaldehyde are flavoring agents and could have 
originated from previously ingested food. Phthalates and Bisphenol A are 
associated with plastics and could originate from particles in the air or vapors 
emitted from the BCD. Considering the ranges of exogenous contamination 
sources it is important to note that some of the tentatively identified compounds 
may not be relevant to that of the exhaled breath of healthy people or smokers. 
7.0 Conclusion 
The present study was aimed at demonstrating the potential of a new 
sorbent device, CMV, for the collection of exhaled breath volatiles and aerosol 
particulates of smokers and nonsmokers. For this purpose, GC/MS coupled to a 
thermal desorption probe was applied for use of the CMV device.  The CMV was 
capable of identifying individual compounds in breath samples of both exogenous 
and endogenous origin totaling 119 compounds collectively over the 20 subjects. 
The identified compounds consisted of various chemical classes. Twelve 
compounds were identified as significant between cigarette treatment group and 
the nonsmoker control group. Nicotine, one of the significantly identified 
compounds and target analyte was detected in 9/13 smoker subjects averaging a 
nicotine concentration of 143 ± 31 pg of cigarette smokers for an approximate 
volume of five liters of breath. The collected breath profiles were distinguishable 
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between smoker and nonsmoker groups when nicotine was detected, resulting in 
zero false positives, but four false negatives.
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CHAPTER 6: LIMITATIONS & FUTURE WORK  
Exhaled breath research has proved to be complex in the execution of its 
sample collection, data analysis and interpretation. Each methodological 
approach to executing this research presents limitations as well as provides 
insight into solutions toward them. The limitations to the sample collection, data 
analysis and interpretation of the research in this study will be reviewed followed 
by suggestions for improvement to the study for future work. 
1.0 Sample Collection Limitations 
The sample collection limitations of this research stem from the lack of 
preparation of the subjects before sampling and the sampling device itself. This 
research did not conduct sampling protocol under the necessary controlled 
conditions to limit the inter-individual variability between subjects. The subjects 
were not asked to submit to any unusual requests in preparation of sample 
collection nor were they monitored in the period before sample collection. In this 
respect, the breath profile and concentration of nicotine from the subject could 
vary based on their smoking preferences and habits. The smoking habits of a 
smoker reflect their style of smoking. Each subject may have differing nicotine 
tolerances contributing toward their choice of cigarette brand, puff volume and 
duration, depth of inhalation, puff hold and cigarette length smoked. If this study 
were to be repeated, it is suggested that more variables are controlled such as 
cigarette brand and smoking style. A more controlled study can help to decrease 
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the inter-individual variability, although other factors such as metabolic 
processing within the body cannot be controlled.   
The sampling device used in this research also contributed to sample 
collection limitations. The sampling device must support standardized collection 
of breath volumes. The flow through BCD used in this study was unable to offer 
the recommended minimum resistance needed in a breath device for comfortable 
collection of controlled breath sample volumes from a volunteer. The diameter of 
the BCD is 7 mm compared to wide tubing of up to 1 inch in diameter reported in 
other studies [50]. Resistance in the BCD could contribute to varying exhaled 
flow rates which are directly connected to exhaled concentration because of the 
relationship of flow rate and contact time of breath with the mucosa of the airway 
before expiration [23]. If this study were to be repeated, efforts would be made to 
hold the BCD at an appropriate temperature (~45 C) during collection to prevent 
condensation of water vapor from the breath where VOCs could partition into the 
aqueous phase. A redesign of the BCD would be suggested to incorporate a 
vacuum to assist in decreasing resistance as well as a meter to observe breath 
flow for inter-individual adjustments for constant volume collection.   
2.0 Data Analysis Limitations 
 
The main limitation of the data analysis of exhaled breath samples were the 
observed contaminations of background interference from the sorbent material 
used in the CMV which have potential to interfere with target analyte 
identification. Some of the common background siloxane interferences observed 
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in the CMV are m/z ions 73, 207, 267, 327, 281, 193. Peaks at m/z 207 and 281 
are hexamethyl-cyclotrisiloxane and octamethyl cyclotertrasiloxane, respectively.  
Proper manufacturing of the CMV device along with proper conditioning before 
use minimized the interferences during analysis. Background contamination 
became problematic for low concentrations as seen in Figure 29. 
 
 
 
Figure 29: (A) Mass spectrum of a 1 µL 500 ppb solution of nicotine spiked onto 
a CMV and (B) mass spectrum of 131 ppb nicotine peak in breath sample of 
subject 34-01.  
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3.0 Data Interpretation Limitations 
Data interpretation of exhaled breath profiles are limited when proper 
action of background elimination is not controlled. Exogenous background 
contamination in exhaled breath can originate from saliva, mouth air or 
contaminated ambient inspired air. Suppression of inspired air contamination 
post sample collection can be achieved by applying the alveolar gradient 
principle to data analysis where the environment is sampled and subtracted from 
the breath sample as described in research by Michael Philips [50]. A pre sample 
collection prevention measure for inspired air contamination is to supply subjects 
with ultrapure breathing air before sampling as demonstrated in protocols of 
previous research studies [35, 50]. A study by Van den Velede and associates 
identified a significant amount of compounds found in mouth air [9] which could 
be contributed by mouth bacterial conditions such as halitosis [94]. Provisions for 
this contamination source can be instilled in the protocol by implementing an oral 
hygiene mouth rinse before sampling.  
4.0 Future Work 
In addition to accounting for all of the previously suggested improvements 
on limitations in this preliminary research, efforts to increase subject recruitment 
should be considered in future work. This research was conducted on a small 
scale, limiting the power of statistical interpretation as well as implying a lack of 
confidence in the results. Increased participation would present clarification on 
any previously identified significant conclusions.  
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Provided the initial promising results of breath collection by CMV, 
investigations into the improvement of the devices’ sampling ability should be 
considered in future work. Aspects under consideration are chemical and 
analytical sensitivity involving new sorbent coatings for the CMV and cryogenic 
focused sample introduction. 
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CHAPTER 7: FUTURE WORK IN MARIJUANA BREATH DETECTION 
The literature review thus far in this thesis has demonstrated that the 
exhaled breath profile of cigarette smokers can be distinguished from 
nonsmokers based on the quantitative and qualitative investigation of VOCS and 
NVOCS which prove to be statistically significant between the groups. 
Theoretically, under this same principle the exhaled breath profile of marijuana 
smokers should be able to be distinguished from nonsmokers. This distinction is 
dependent on the VOCS and NVOCS observed in the exhaled breath samples 
and the capability and sensitivity of an analytical technique in their measurement.  
1.0 Preliminary Study: Headspace Analysis of Seized Marijuana Plant Material by 
CMV-GC/MS 
	
Chapter 5 of this thesis has demonstrated the CMV’s ability to detect 
constituents of cigarette smoke by way of absorption and excretion from the lung 
airways in exhaled breath. In attempts to demonstrate the CMV’s potential to 
detect constituents in marijuana smoke by way of absorption and excretion from 
the lung airways in exhaled breath, preliminary studies examining the headspace 
vapor of marijuana plant material (PM) was used to demonstrate detectable 
fractions by dynamic CMV sampling. The observed fractions were expected to be 
analogous with some in marijuana smoke, and therefore expected to be available 
to be inhaled and subsequently exhaled in breath. Description of this experiment 
will follow.    
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1.1 Introduction to Marijuana Analysis  
Trained canines are routinely employed in the detection of marijuana 
plants by associating the presence of the volatile compounds emitted by the 
plant. Alternative analytical methods to the use of canines have been recently 
proposed for use by law enforcement. The headspace of marijuana is classified 
into four categories (i.e., fractions) on the basis of the compounds’ physical 
properties. The classifications are termed fractions and are described as follows: 
(I) volatiles (bp 20-80˚C; MW<100 g/mol), (II) intermediate volatiles (bp 150-
198˚C; MW>100 g/mol), (III) less volatiles (bp>198˚C; MW>200 g/mol), and (IV) 
non volatiles (bp>200˚C; MW>300 g/mol) [95]. The identified fractions of a 
particular marijuana sample are dependent upon the operational conditions of the 
analytical technique as well as its sample preparation procedure. The following 
previous studies have investigated the examination of marijuana headspace 
where variable results were produced.  
Traditional headspace analysis of marijuana using a marijuana standard 
(grown from Mexican seed containing 1.9% THC content) was first demonstrated 
by Hood and associates, implementing gas tight syringes to extract volatiles for 
direct GC/MS analysis. The analysis of one gram of a marijuana standard sample 
heated at 65˚C for one-hour equilibrium time, resulted in the detection of 20 
compounds [96]. A decade later Osman and colleagues, demonstrated the 
benefits of the preconcentration of volatiles onto Tenax® sorbent tubes in 
comparison to traditional headspace analysis using gas tight syringes. Their 
examination of the β-caryophyllene volatile in a 100 mg sample of 10-year-old 
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cannabis resin heated to 100˚C demonstrated that Tenax® tubes for TD-GC/MS 
resulted in much improved detection limits over HS-GC/MS with gas tight 
syringes at 3 mg and 10 mg, respectively [97]. 
With the introduction of SPME technology, Illias and associates focused 
on the examination of the cannabinoids considered the “nonvolatile fraction” in 
marijuana headspace according to these authors. Ten cannabinoids were 
extracted from 60 mg of powdered marijuana plants heated to 150˚C, to 
distinguish between marijuana grown in different regions [98]. Continuing in the 
direction of pre-concentration techniques, Rothschild and associates, used a 
Porapak Q mesh adsorbent to pre-concentrate volatiles of flowering male and 
female cannabis plant pollen, before solvent extraction followed by GC/MS 
analysis. Marijuana pollen and plant volatiles were distinguished from each other, 
as well as 68 compounds were identified [99]. 
As researchers such as Wu & Chang demonstrated that thermal 
desorption methods statistically demonstrated better repeatability and recovery 
than the classic solvent extraction method in ambient air volatile analysis [46], 
new sorbent technologies were developed. One such technology was the CMV 
whose physical and chemical characteristics have been previously described in 
Chapter 1, Section 2.1. In addition to its forensic applications in explosive 
detection [16] and gunshot residue detection [18], the CMV has also been used 
to detect the volatiles of drugs including marijuana [20].  The CMV-GC/MS 
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marijuana headspace studies of a single 25 g packaged marijuana sample kept 
at equilibrium for 3 hours resulted in the identification of 26 compounds [20]. 
In this study, the CMV explored the headspace profile of seized marijuana 
PM. In addition, the potential of the CMV device for the detection of marijuana 
plants by association of the VOCs detected, was evaluated. Finally, the analytical 
figures of merit for the detection of the VOCs are also reported.    
1.2 Instrumentation 
Analysis was performed on an Agilent 7890A Gas Chromatograph (GC) 
and an Agilent 5975C Inert XL MSD mass spectrometer (Santa Clara, CA). 
Chromatographic separation occurred on a HP-5ms capillary column (29.17 m x 
0.25 mm x 0.25 µm). The oven temperature was programmed for 2 min at 40˚C, 
then 25˚C/min to 260˚C, and finally in 260˚C for 10 min. Injector was operated in 
splitless mode at 270˚C and the transfer line was 280˚C. The constant GC 
column flow of helium was 1.2 ml/min. The mass spectrometer simultaneously 
collected TIC and SIM data.  The THC ions selected for ion monitoring were 
target ion 299 m/z and qualifier ions 271, 231, 314 m/z over the acquisition range 
40-340 m/z. 
1.3 Materials 
A description of the assembly of the CMV device used for the headspace 
analysis have been previously described [16]. Before sampling, the CMV devices 
were conditioned for 2 hours in an oven at 250˚C. After conditioning, the CMVs 
were blanked to record their baseline background in the GC/MS via coupling with 
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the Agilent TSP (Santa Clara, CA). The CMVs have been reported to withstand 
several extraction and desorption cycles and were wrapped in aluminum foil and 
labeled for storage and transport between sampling uses.   
1.3.1 Reagents  
 
Separate experiments of standard compounds diluted with GC grade 
methanol (Fischer Scientific, Waltham, MA) were analyzed to confirm retention 
time and mass spectra by comparison of compounds identified in marijuana 
headspace profile. Compounds limonene, α-pinene, octadecane and β-pinene 
were from Acros Organics (Morris Plains, NJ), nicotine, β-caryophyllene,            
α-humulene, dodecane, tetradecane, tridecane, benzyl alcohol, benzaldehyde, 
nonanal, eicosane, heneicosane, tricosane, and THC from Sigma-Aldrich (St. 
Louis, MO), and linalool from Fluka (Buchs, Switzerland).   
1.3.2 Samples 
 
Confirmed marijuana plant samples were analyzed within a local forensic 
laboratory as a result of drug seizures. The eight marijuana samples analyzed in 
this study are described in Table 10.   
1.4 Sample Collection Methods  
Marijuana sample seizures consisted of various quantities of marijuana 
bags. Only a grab sample consisting of an individual marijuana bag was 
analyzed from each marijuana evidence seizure, except for sample 2, where the 
entire sample seizure was analyzed as a whole. The headspace directly above 
the PM inside the ziplock bags was taken for all samples except for sample two. 
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For sample two, the headspace of a paper bag containing loose tobacco leaves 
and sealed marijuana baggies was taken. Before sampling of the first marijuana 
seizure began, a blank of the laboratory air and the air in the fume hood, where 
samples would be handled, were taken to ensure no contamination of the 
sample. Sampling did not occur under optimized conditions because of limited 
access to samples. Headspace sampling was performed by affixing a CMV to the 
end of a Supelco MSA Elf air sampling pump (Bellefonte, PA) and hovering the 
CMV in the opening of the opened ziplock baggies for 1 minute at an extraction 
flow rate of 1 L/min. Duplicate samples of each marijuana seizure was taken with 
a 1-minute waiting period between sampling with the zip opening closed. After 
each sampling the CMV was wrapped in foil and the sampling end of the CMV 
was noted for proper insertion orientation during GC/MS analysis. A trip blank 
CMV was taken as a control. CMVs were transported back to lab under an 
icepack to prevent loss. GC/MS analysis was performed immediately on fume 
hood and laboratory air blanks and the first replicate of all the marijuana sampled 
CMVs. The trip blank and the second replicates of the marijuana sampled CMVs 
were individually sealed in glass vials and refrigerated overnight for next day 
analysis.     
1.5 Results and Discussion  
The headspace of numerous seizure samples of PM suspected to be 
marijuana were examined and similar headspace profiles were obtained.  
Acquisition of chromatographic data was performed using Agilent Chemstation  
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Table 10: Description of the seized marijuana samples provided from a local 
forensic laboratory. 
 
software and computer mass spectrum reference libraries NIST 2008 and WILEY 
2008 were applied for identification reporting the match quality percent of those 
generally higher than 60%. Where standards were available, identification was 
further confirmed by standard solution retention time and mass spectra of 
specific compounds indicated in Table 11. In this study, 44 compounds were 
identified as a part of the marijuana headspace profile between the eight 
marijuana seizures, with fourteen confirmed by a standard solution (Table 11). 
The samples (1-8 in Table 10) individually contained 29, 28, 33, 37, 17, 34, 34, 
and 36 compounds, respectively.  All sample seizure varieties contained            
Sample 
Number 
 
Sample description 
Seizure 
Date 
(MM/YYYY) 
Dimensions 
of 
packaging 
(mm x mm) 
Weight 
of 
sample 
(g) 
1 Clear plastic ziplock w/ 
compressed plant material 09/2014 50 x 63  4.084 
2 Brown lunch bag w/ loose 
tobacco leaves and sandwich 
bag of ziplock baggies w/ plant 
material   
01/2015 - 37 
3 Clear plastic ziplock w/ 
compressed plant material 10/2014 50 x 63  5.483 
4 Blue plastic ziplock w/ 
compressed plant material 04/2015 32 x 33 0.741 
5  Clear plastic vials w/ loose 
plant material 03/2014 40 x 18 3.394 
6 Clear plastic ziplock w/ 
compressed plant material 05/2013 50 x 63  6.496 
7 Clear plastic ziplock w/ 
compressed plant material 03/2014 38 x 43 1.641 
8 Clear plastic ziplock w/ 
compressed plant material 04/2015 50 x 53 3.136 
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α-pinene, α-terpinolene, β–linalool, borneol, dodecane, tridecane, tetradecane, 
valencene, eicosane, and tricosane. Thirty-five compounds, as follows, were 
non-inclusively consistent with those reported from multiple literature sources: 
α-pinene [96, 99-106], benzaldehyde [104, 105], β-myrcene [20, 96, 99-106],     
β-pinene [20, 96, 99, 101-106], 3-carene [20,96, 99, 102, 104-106],                    
2-ethylhexanol [104, 105], limonene [20, 96, 99-106], benzyl alcohol [99, 104-
106], β–ocimene [96, 99, 101-103, 106], ү-terpinene [20, 96, 104-106],               
α-terpinolene [96, 99, 102, 104-106], β-linalool [20, 96, 99, 102, 104-106], 
nonanal [104-106], exo-fenchol [96, 99, 104-106], borneol [104,106], dodecane 
[104, 106], tridecane [104-106], ylangene [99, 106], 4,11–selinadiene [106],      
α–zingiberene [99], α-bergamotene [96, 99, 106], α-santalene [106],                   
β-caryophyllene [96, 97, 99, 106], α-humulene [20, 96, 99, 102-106], α-guaiene 
[20, 104-106], β-guiaene [20], α-gurjunene [99, 104, 105], valencene [20, 103-
105], 3,7(11)–selinadiene [20, 103, 106], β–maaliene [103], guaiol [99, 103, 106], 
α–bisabolol [99, 104-106], octadecane [106], THC [98] and cannabinol (CBN) 
[98].  
Twelve compounds were consistent with those reported in previous CMV-
GC/MS marijuana studies [20]. The following 20 compounds identified in this 
study are consistent with other literature sources, but not previously reported by 
CMV detection until this study: α-pinene, benzaldehyde, benzyl alcohol,             
β–ocimene, α-terpinolene, nonanal, exo-fenchol, borneol, dodecane, tridecane, 
ylangene, α–zingiberene, α-bergamotene, β-caryophyllene, α-gurjunene,          
β–maaliene, guaiol, α–bisabolol, THC, and CBN. It is of interest to note that the  
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Table 11: Qualitative analysis of compounds identified to be emitted from 
headspace of marijuana samples captured by CMV after 1 min dynamic sampling 
at 1 L/min extraction flow.  
 
 
No. 
Retention 
Time 
(min) 
Compound Confirmation 
Match 
Quality 
Percent 
VOC 
sample 
Frequency 
(n=8) 
 
1 6.079 α-pinene L 76% 8/8 
2 6.283 Benzaldehyde S 90% 2/8 
3 6.304 β–myrcene L 80% 5/8 
4 6.430 β–pinene S 89% 3/8 
5 6.619 3-carene L 83% 1/8 
6 6.683 2-ethylhexanol L 72% 7/8 
7 6.746 Limonene S 91% 3/8 
8 6.767 Benzyl Alcohol S 96% 5/8 
9 6.823 Β-ocimene L 96% 2/8 
10 6.942 γ-terpinene L 97% 5/8 
11 7.131 α-terpinolene L 96% 8/8 
12 7.181 β-linalool S 96% 8/8 
13 7.209 Nonanal S 93% 6/8 
14 7.536 Allo-Ocimene L 97% 4/8 
15 7.391 Exo-Fenchol L 96% 7/8 
16 7.728 Borneol L 91% 8/8 
17 7.777 Dodecane  S 96% 8/8 
18 8.352 Tridecane S 98% 8/8 
- 8.738 Nicotine* S 96% 1/8 
19 8.857 Ylangene L 99% 5/8 
20 8.885 Tetradecane S 91% 8/8 
21 8.920 Surfynol L 83% 5/8 
22 8.962 α-zingiberene L 72% 2/8 
23 9.060 α-bergamotene L 96% 3/8 
24 9.095 α- santalene L 99% 4/8 
25 9.166 β-caryophyllene L 99% 7/8 
26 9.271 cyclododecane L 94% 2/8 
27 9.348 α-humulene L 97% 7/8 
28 9.474 4,11–selinadiene L 96% 6/8 
29 9.516 Seychellene L 93% 7/8 
30 9.544 α- guiaene L 93% 7/8 
31 9.664 β-guaiene L 62% 7/8 
32 9.699 α- gurjunene L 96% 5/8 
33 9.748 Valencene L 90% 8/8 
34 9.776 3,7,(11)-selinadiene L 98% 6/8 
35 9.846 β–maaliene L 92% 2/8 
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Table 11 (Continued) 
 
 
No. 
Retention 
Time 
(min) 
Compound Confirmation 
Match 
Quality 
Percent 
VOC 
sample 
Frequency 
(n=8) 
 
36 9.993 Guaiol L 99% 6/8 
37 10.330 α–campholene 
aldehyde 
L 52% 7/8 
38 10.365 α–bisabolol L 90% 6/8 
39 11.779 Octadecane L 86% 7/8 
40 11.663 Eicosane S 92% 8/8 
41 12.175 Heneicosane S 90% 7/8 
42 13.465 Tricosane S 94% 8/8 
43 15.862 THC S *SIM 6/8 
44 16.754 CBN L 46% 3/8 
* Nicotine is not associated with the headspace profile of marijuana but of the tobacco leaves 
present in that particular sample.  
Compound identification confirmed by retention time of standard solutions (S) or mass 
spectrum in library (L). 
THC was confirmed by the following selected ions 299, 231, 271, 314 m/z. 
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following nine compounds found by CMV have not previously been reported as 
constituents of marijuana headspace in any literature: allo-ocimene, surfynol, 
tetradecane, cyclododecane, seychellene, α-campholene aldehyde, eicosane, 
heneicosane, and tricosane. 
Sample seizures numbers four, eight, and one respectively showed great 
intensity in their chromatographic response for the monoterpenes such as α-
pinene, β-myrcene, and limonene and sesquiterpenes such as β-caryophyllene, 
α-humulene, and α-guaiene. An example chromatogram showing the profile of 
marijuana headspace is shown in Figure 31B. As seen from the chromatogram 
and list of compounds in Table 11 the chromatographic method and sampling in 
this study has only identified compounds in the second fraction (monoterpenes), 
third fraction (sesquiterpenes) and the fourth fraction (cannabinoids). The 
oxygenated compounds of the first fraction are commonly identified in most plant 
vapors [96] and are not particularly indicative of marijuana specifically. The 
sesquiterpene, β-caryophyllene, is usually found to be more concentrated and 
odorous than other compounds [105]. This can be seen in Figure 31 comparing 
the unpackaged (B) to the packaged (C) marijuana headspace profiles. The 
packaged marijuana sample (seizure #2) contained a minimum of 75% of the 
same compounds identified in the other seven unpackaged sample seizures. The 
compounds are present, but just at different concentrations. The SPME-
MDGC/MS-O studies by Rice & Koziel of one gram of packaged and unpackaged 
air-dried marijuana revealed that packaging was not significant in volatile 
detection. Sample 5 had the least amount of compounds identified, and was also 
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the only sample that did not contain β-caryophyllene. It is hypothesized that, that 
particular PM was older than the others, since it did not contain the most odorous 
compound known to be present in the marijuana. This hypothesis was 
additionally supported by the visual appearance of the PM as it was brown and 
appeared to be dried out, compared to the green appearance of the other 
samples. 
Each replicate of each sample seizure was analyzed separately and the 
detected compounds between each were combined for a total representation of 
the sample as a whole. Compounds present between duplicate sampling of each 
seizure were generally consistent with each other. Compound identification of the 
marijuana headspace profile did not include compounds consistent with the 
contaminants found in the trip, fume hood and laboratory air blanks. Some of the 
contaminants identified in the blanks were dibutyl phthalate, diethyl phthalate, 2-
phenoxyethanol and 1-phenoxypropan-2-ol.  A comparison of the chromatogram 
of the laboratory air blank and an example chromatogram of a marijuana 
headspace profile is shown in Figure 31A and Figure 31B. 
Figure 30, illustrates the identification of the THC in the chromatogram of 
marijuana headspace sample #8, with the confirmation by mass spectrum (data 
not shown). It is of interest to note the peculiarity of the identification of 
cannabinoids THC and CBN in the marijuana samples occurred under the room 
temperature sampling conditions as described in this study. Cannabinoids occur 
mainly in their carboxylic acid derivative form in the plant and are not usually 
released until the sample is heated since they decarboxylate slowly at room 
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temperature [98]. Since the direct detection of cannabinoids are unlikely at room 
temperature based on their low vapor pressure, it is hypothesized that THC and 
CBN entered the CMV absorbed on particles (possibly marijuana pollen 
particles). Rothschild and associates, reported that benzyl alcohol was 
exclusively found in marijuana pollen. Of the six occurrences of THC identified in 
the marijuana profile, three of those also identified benzyl alcohol in samples 
three, six and seven, respectively.   
  
Figure 30: (A) Total ion chromatogram of the VOC profile of marijuana 
headspace sample #8, emphasizing THC peak at 15.855 min and (B) the direct 
spike response of 1 ppm THC in a MeOH solution on CMV; peak at 15.855 min. 
A calibration curve of liquid THC solutions spiked onto CMVs, showed 
linearity (R2=0.99) over concentration range of 0.5-20 ppm (0.5, 1.0, 2.5, 5.0, 
10.0, 15.0, 20.0 ppm). The average of three replicates over the 5-20 ppm 
concentration range showed relative standard deviations of ≤12%, while 0.5-2.5 
ppm concentration range showed relative standard deviations of ≤26%. The limit 
of detection of THC on CMV is 1.0 ng.  An approximation of the mass of THC 
collected on the CMV from marijuana sample #8, was determined to be 1.8 ng 
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after integration of the THC peak in the sample and use of calibration curve 
[Chapter 3, Section 2.0, Figure 9].   
Statistical analysis was used to examine the relationship of packaged and 
unpackaged marijuana headspace profiles. One-way analysis of variance 
(ANOVA) and Tukey’s honest significant difference test (Tukey HSD) was 
performed on the eight marijuana samples using the data from the peak area 
under the curve of the identified compounds in order to determine if the samples 
headspace profiles are different from each other. P values of <0.05 were 
considered as significant for one-way ANOVA. One-way ANOVA resulted in p-
value of 0.000284 (p<0.05) which indicated that there was a significant difference 
between one or more of the eight marijuana samples. A comparison between 
each sample was examined using the Tukey HSD test to identify which pairs 
were significantly different from each other. Results are summarized in Table 12. 
There was a significant difference between sample four and all other samples 
except samples 1 and 8. It is hypothesized that samples 4 and 8 are not 
significantly different because they were most recently seized on the same date 
of 4/2015. The significance of samples 4,8, and 1 could be a result of their 
difference in concentration as they were more concentrated in certain 
monoterpenes and sesquiterpenes. Just as represented in the Rice & Koziel 
studies the headspace profile through the packaged sample #2 and the 
remaining unpackaged headspace marijuana profiles were not significantly 
different. 
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Figure 31: Total ion chromatogram of laboratory room air (A), profile of headspace over open 
marijuana sample #4 (B), and profile of headspace through packaging of marijuana sample #2 
(C). Characteristic peak identification of marijuana sample identified according to compounds in 
Table 11.  
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Table 12: Statistical analysis of the eight marijuana sample seizures using Tukey 
HSD test.  
Sample Comparison P-value Significance 
Sample 1 vs Sample 2 0.8999 N.S. 
Sample 1 vs Sample 3 0.8999 N.S. 
Sample 1 vs Sample 4 0.1168 N.S. 
Sample 1 vs Sample 5 0.7933 N.S. 
Sample 1 vs Sample 6 0.8999 N.S. 
Sample 1 vs Sample 7 0.8673 N.S. 
Sample 1 vs Sample 8 0.8999 N.S. 
Sample 2 vs Sample 3 0.8999 N.S. 
Sample 2 vs Sample 4 0.0093 P<0.01 
Sample 2 vs Sample 5 0.8999 N.S. 
Sample 2 vs Sample 6 0.8999 N.S. 
Sample 2 vs Sample 7 0.8999 N.S. 
Sample 2 vs Sample 8 0.8999 N.S. 
Sample 3 vs Sample 4 0.0020 P<0.01 
Sample 3 vs Sample 5 0.8999 N.S. 
Sample 3 vs Sample 6 0.8999 N.S. 
Sample 3 vs Sample 7 0.8999 N.S. 
Sample 3 vs Sample 8 0.7563 N.S. 
Sample 4 vs Sample 5 0.0010 p<0.01 
Sample 4 vs Sample 6 0.0022 P<0.01 
Sample 4 vs Sample 7 0.0013 P<0.01 
Sample 4 vs Sample 8 0.2228 N.S. 
Sample 5 vs Sample 6 0.8999 N.S. 
Sample 5 vs Sample 7 0.8999 N.S. 
Sample 5 vs Sample 8 0.6234 N.S. 
Sample 6 vs Sample 7 0.8999 N.S. 
Sample 6 vs Sample 8 0.7710 N.S. 
Sample 7 vs Sample 8 0.6974 N.S. 
*Results	were	obtained	using	an	online	calculator	at		
http://statistica.mooo.com/OneWay_Anova_with_TukeyHSD_result	
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1.6 Conclusions 
This study demonstrated a method for analysis of the volatile headspace 
of multiple seized marijuana samples from a local forensic laboratory employing 
CMV adsorption/desorption analysis. The sorption technology of the CMV 
sufficiently identified 44 compounds in the headspace of marijuana, 35 of which   
are consistent with eleven previously published studies. The remaining nine 
compounds allo-ocimene, surfynol, tetradecane, cyclododecane, seychellene,   
α-campholene aldehyde, eicosane, heneicosane, and tricosane have not 
previously been reported in the marijuana headspace profile. The CMV’s 
simplicity showed its usefulness for the forensic application of identifying 
unknown PM as marijuana by its capability of identifying its volatiles. Although 
the reported method is different from those in previous studies, specific 
compounds and overall similarity in the composition of the marijuana headspace 
profile has been demonstrated.  
2.0 Implications of Preliminary Study for Future Research  
The methodological sampling approach of the CMV has demonstrated its 
ability to detect the chemical fractions available in marijuana PM. Studies have 
demonstrated the similarity of VOCs present in the headspace of marijuana PM 
and marijuana plant extract toward the VOCs present in marijuana smoke 
condensate [100, 107]. It is expected that additional compounds will be observed 
in marijuana smoke as the burning of marijuana creates pyrolysis and 
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combustion byproducts. Studies have also demonstrated the chemical similarities 
of cigarette smoke and marijuana smoke [52, 108].  
Provided their similarities it would not be unreasonable to suggest that the 
CMV would be capable of detecting marijuana smoke by way of absorption and 
excretion from the lung airways in exhaled breath for purposes of distinguishing 
between marijuana smokers and nonsmokers. One burdening objective to this 
project would be the identification of significant VOCs necessary for the 
distinction of the groups. Differences in marijuana smoke and cigarette smoke 
reveal multiple classes of terpenes and cannabinoids which are only found in 
marijuana smoke [95]. Contingent upon their quantitative representation in the 
smoke, they should be theoretically found in exhaled breath after smoking 
marijuana. Exhaled breath research of marijuana smokers have focused on the 
detection of THC and its metabolites [See Chapter 4, Section 1.1] and not any 
other compounds associated with other fractions of marijuana plant. Evaluation 
of THC detection by CMV, using nicotine detection by CMV as a proxy will be 
discussed. 
2.1 Nicotine as a proxy for THC  
Nicotine was a convenient surrogate model for studying the exhalation of 
drugs administered through smoke inhalation, as it was legally accessible in 
comparison to the legal constraints placed around the research of THC and 
marijuana in the state of Florida. However, the chemical and physical properties 
of the drug must be reviewed for comparison and evaluation of the 
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appropriateness of nicotine as its surrogate. Some chemical and physical 
properties of nicotine and THC are listed in Table 13. 
Table 13: Physical and chemical properties of nicotine and THC [84]. 
 THC Nicotine 
Vapor Pressure 4.63 x 10-8 mm Hg @ 25˚C 3.8 x 10-2 mm Hg @ 25˚C 
Boiling Point 157˚C 247.57˚C 
Flash Point 149.3˚C 101˚C 
Henry constant 1.56 x 10-8 atm*m3/mol 3.47 x 10-8 atm*m3/mol 
Log P 6 1.1 
MW 314.5 g/mol 162.2 g/mol 
 
 Breath analysis reviews have suggested that compounds found in breath 
need a sufficient vapor pressure to be released [84]. Nicotine is semi-volatile in 
its free base form, but THC is nonvolatile. Under these assumptions it would be 
assumed that THC would not be detectable in breath, however that statement is 
inconsistent with published literature [See Chapter 4, Section 1.1]. Research 
clarifying the elimination conditions of THC in breath has not been well 
established. However, it is hypothesized that THC molecules are carried in 
breath adhered on aerosol particles. Hence the importance of capturing particles 
as well as capturing gas phase volatiles.     
2.2 Evaluation of the CMV’s Potential for THC Detection  
The long pentyl side chain of the THC structure permits adequate Van der 
Waal force interactions with the siloxane groups of the PDMS coating of the CMV. 
The limit of detection of THC on CMV as reported in Table 1 of Chapter 3 is 84 pg. 
Considering the detectable concentration ranges of THC in the literature, it is 
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plausible that CMV technology would be capable of detecting THC in breath of 
marijuana smokers under appropriate detection windows. 
Successful detection of THC by CMV would provide recent research 
analyzing THC in breath by a direct sampling and desorption extraction method, 
as solvent extraction is the current popular approach of THC detection in breath. 
It would demonstrate the application of CMV as an appropriate breath analysis 
confirmatory method for active ingredients of marijuana in the breath of recent 
marijuana smokers to reveal recent drug use. This technique has the capability to 
be made portable, which could aid law enforcement management of drug impaired 
drivers in traffic patrols, similar to breathalyzers for drunk drivers
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CHAPTER 8: OVERALL CONCLUSIONS 
The current study has demonstrated a clear potential of the CMV device 
as a non-invasive alternative sampling technique to current Tenax® sorbent 
tubes or SPME fibers for the detection and tentative identification of compounds 
in exhaled breath by thermal desorption GC/MS.  
Within the limits of the experimental set up of the GC/MS method, it was 
concluded that the CMV can individually identify the endogenous and exogenous 
compounds in exhaled breath samples of cigarette smoker and nonsmoker 
volunteers. The resulting profile was not 100% diagnostic of a breath profile, but 
characteristic enough to distinguish between the two groups. Twelve compounds, 
including nicotine were statistically significant between the groups’ breath 
profiles. Nicotine was detectable in 69% of smokers with a limit of detection in the 
lower pictogram range (absolute mass detected). Preliminary experiments on the 
headspace of marijuana PM offered insight on the expectations of CMV breath 
detection of marijuana smokers using THC as a target analyte.  
This research exploring the idea of the CMV as a breath sampling device 
for nicotine detection acted as a proof of concept, and suggests sufficient 
reasoning for continued research and development of this application toward the 
detection of THC in the exhaled breath of marijuana smokers. 
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